U.S. patent application number 10/073644 was filed with the patent office on 2003-05-01 for human monoclonal antibodies to fc alpha receptor (cd89).
Invention is credited to Hudson, Debra, van de Winkel, Jan G.J., van Dijk, Marcus A..
Application Number | 20030082643 10/073644 |
Document ID | / |
Family ID | 26952868 |
Filed Date | 2003-05-01 |
United States Patent
Application |
20030082643 |
Kind Code |
A1 |
Hudson, Debra ; et
al. |
May 1, 2003 |
Human monoclonal antibodies to FC alpha receptor (CD89)
Abstract
Human monoclonal antibodies which bind specifically to Fc alpha
receptor (CD89), including monoclonal antibodies which react
specifically to Fc receptor for IgA of human effector cells are
disclosed. The binding agents, e.g., antibodies are useful for
targeting human effector cells (e.g. macrophages) against a target
cell (e.g. a cancer cell, an infectious agent, etc.). For this
purpose, bifunctional antibodies or heteroantibodies can be
constructed containing the binding region derived from an
anti-Fc-alpha receptor antibody and the binding region of a
target-specific antibody. Targeted effector cells can specifically
lyse target cells.
Inventors: |
Hudson, Debra; (Livermore,
CA) ; van Dijk, Marcus A.; (Bilthoven, NL) ;
van de Winkel, Jan G.J.; (Zeist, NL) |
Correspondence
Address: |
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON
MA
02109
US
|
Family ID: |
26952868 |
Appl. No.: |
10/073644 |
Filed: |
February 11, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60338956 |
Nov 5, 2001 |
|
|
|
60268075 |
Feb 12, 2001 |
|
|
|
Current U.S.
Class: |
435/7.21 ;
435/334; 435/70.21; 530/388.22 |
Current CPC
Class: |
A61P 31/00 20180101;
A61P 31/12 20180101; A61K 2039/505 20130101; A61K 47/6879 20170801;
A61P 19/02 20180101; A61P 31/08 20180101; A61P 29/00 20180101; A61P
37/08 20180101; A61P 35/02 20180101; A61P 19/08 20180101; A61P
27/02 20180101; A61P 17/14 20180101; A61P 17/02 20180101; A61P 7/04
20180101; A61P 17/00 20180101; A61P 25/00 20180101; A61P 27/16
20180101; C07K 2319/00 20130101; A61P 13/08 20180101; A61P 17/06
20180101; A61P 1/04 20180101; A61P 1/16 20180101; A61P 7/06
20180101; C07K 2317/77 20130101; A61P 11/06 20180101; C07K 2317/21
20130101; A61P 13/12 20180101; A61P 15/00 20180101; C07K 16/283
20130101; G01N 33/6863 20130101; A01K 2217/05 20130101; A61P 35/00
20180101; A61P 37/06 20180101; A61P 21/04 20180101; G01N 2333/70535
20130101; A61P 3/10 20180101; A61P 37/00 20180101 |
Class at
Publication: |
435/7.21 ;
530/388.22; 435/334; 435/70.21 |
International
Class: |
G01N 033/567; C12P
021/04; C12N 005/06; C07K 016/28 |
Claims
We claim:
1. An isolated human monoclonal antibody which binds to human
CD89.
2. The isolated human monoclonal antibody of claim 1, wherein the
antibody does not activate complement.
3. The isolated antibody of claim 1, wherein the antibody binds to
CD89 at a site which is distinct from the IgA binding site of the
receptor.
4. The isolated human monoclonal antibody of claim 1, wherein the
antibody inhibits IgA binding to CD89.
5. The isolated human monoclonal antibody of claim 4, wherein the
antibody inhibits IgA binding to CD89 by at least about 50%.
6. The isolated human monoclonal antibody of claim 1, wherein the
antibody binds to human CD89 with an equilibrium association
constant (K.sub.a) of at least 10.sup.8 M.sup.-1.
7. The isolated human monoclonal antibody of claim 1, wherein the
antibody binds to human CD89 with an equilibrium association
constant (K.sub.a) of at least 10.sup.9 M.sup.-1.
8. The isolated human monoclonal antibody of claim 1, wherein the
antibody heavy chain is an IgG1 heavy chain and the antibody light
chain is a kappa light chain.
9. The isolated human monoclonal antibody of claim 1 comprising a
heavy chain encoded by the nucleic acid comprising the nucleotide
sequence selected from the group consisting of SEQ ID NOs: 1 and 5
and a light chain encoded by the nucleic acid comprising the
nucleotide sequence selected from the group consisting of SEQ ID
NOs: 3 and 7, and conservative sequence modifications thereof.
10. The isolated human monoclonal antibody of claim 1 comprising a
heavy chain comprising the amino acid sequence selected from the
group consisting of SEQ ID NOs: 2 and 6 and a light chain
comprising the amino acid sequence selected from the group
consisting of SEQ ID NOs: 4 and 8, and conservative sequence
modifications thereof.
11. An isolated human monoclonal antibody which binds to human CD89
and has at least one characteristic selected from the group
consisting of: (a) a binding equilibrium association constant (Ka)
to human CD89 of at least about 10.sup.7 M.sup.-1; (b) a
dissociation constant (Kd) from human CD89 of about 10.sup.-8
S.sup.-1 or less; (c) absence of in vivo complement activation upon
binding to human CD89; (d) the antibody binds to an epitope on
human CD89 which does not inhibit human IgA binding to the
receptor; (e) the antibody comprises a heavy chain comprising an
amino acid sequence selected from the group consisting of SEQ ID
NOs: 2 and 6 and conservative sequence modifications thereof, and a
light chain comprising an amino acid sequence selected from the
group consisting of SEQ ID NOs: 4 and 8 and conservative sequence
modifications thereof.
12. The isolated human monoclonal antibody of claim 1, wherein the
antibody is a Fab fragment or a single chain antibody.
13. The isolated human monoclonal antibody of claim 1, wherein the
antibody is produced by a hybridoma which includes a B cell
obtained from a transgenic non-human animal having a genome
comprising a human heavy chain transgene and a human light chain
transgene fused to an immortalized cell.
14. A hybridoma comprising a B cell obtained from a transgenic
non-human animal having a genome comprising a human heavy chain
transgene and a human light chain transgene fused to an
immortalized cell, wherein the hybridoma produces a detectable
amount of a human monoclonal antibody according to claim 1.
15. The hybridoma of claim 14 selected from the group consisting of
the hybridomas designated as 7.4, 8.2 and 14.1.
16. An isolated human monoclonal antibody which binds to an epitope
on human CD89 defined by an antibody selected from the group
consisting of mAbs 7.4, 8.2 and 14.1.
17. An isolated human monoclonal antibody which binds to an epitope
on human CD89 defined by mAb 14.1 having a heavy chain amino acid
sequence shown in SEQ ID NO: 2 and a light chain amino acid
sequence shown in SEQ ID NO: 4.
18. An isolated human monoclonal antibody which has the binding
characteristics of an antibody selected from the group consisting
of mAbs 7.4, 8.2, and 14.1.
19. An isolated human monoclonal antibody which has the binding
characteristics of mAb 14.1 having a heavy chain amino acid
sequence shown in SEQ ID NO: 2 and a light chain amino acid
sequence shown in SEQ ID NO: 4.
20. A transgenic non-human animal which expresses the antibody of
claim 1, wherein the transgenic non-human animal has a genome
comprising a human heavy chain transgene and a human light chain
transgene.
21. A method of producing an antibody of claim 1, comprising:
immunizing a transgenic non-human animal having a genome comprising
a human heavy chain transgene and a human light chain transgene
with CD89 or a cell expressing CD89 such that antibodies are
produced by B cells of the animal; isolating B cells of the animal;
and fusing the B cells with myeloma cells to form immortal,
hybridoma cells that secrete the antibody.
22. A bispecific or multispecific molecule comprising the human
antibody of claim 16 and a portion which binds to a target antigen
other than CD89.
23. The bispecific or multispecific molecule of claim 22, wherein
the antibody is an Fab fragment or a single chain antibody.
24. The bispecific or multi specific molecule of claim 22, wherein
the target antigen is a tumor antigen.
25. The bispecific or multispecific molecule of claim 22, wherein
the portion that binds to the target antigen comprises an antibody
or a tumor ligand.
26. The bispecific or multispecific molecule of claim 22 comprising
a fusion protein.
27. The bispecific or multispecific molecule of claim 22 comprising
a chemically linked conjugate.
28. The bispecific or multispecific molecule of claim 22 which
induces lysis (ADCC) of a cell expressing the target antigen in the
presence of effector cells expressing CD89.
29. The bispecific or multispecific molecule of claim 22, wherein
the antigen is selected from the group consisting of
carcinoembryonic antigen (CEA), gastrin releasing peptide receptor
antigen (GRP), mucine antigens, epidermal growth factor receptor
(EGF-R), HER2/neu, HER3, HER4, CD20, CD30, MAGE antigens, SART
antigens, MUC1 antigen, c-erb-2 antigen and TAG 72.
30. A molecular conjugate comprising the human antibody of claim 16
linked to an antigen.
31. The molecular conjugate of claim 30, wherein the antibody is an
Fab fragment or a single chain antibody.
32. The molecular conjugate of claim 30 comprising a fusion
protein.
33. The molecular conjugate of claim 30 comprising a chemically
linked conjugate.
34. The molecular conjugate of claim 30, Wherein the antigen
35. A composition comprising the human antibody of claim 1 and a
pharmaceutically acceptable carrier.
36. A composition comprising the bispecific molecule of claim 22
and a pharmaceutically acceptable carrier.
37. A composition comprising the molecular conjugate of claim 30
and a pharmaceutically acceptable carrier.
38. A composition comprising a combination of two or more human
antibodies of claim 1, wherein each of said antibodies binds to a
distinct epitope of human CD89.
39. The composition of claim 35 further comprising a cytotoxic
agent.
40. An immunotoxin comprising the antibody of claim 2 linked to a
cytotoxic agent.
41. A method of inhibiting growth of a cell comprising contacting
the cell with an effective amount of the bispecific antibody of
claim 22 such that growth of the cell is inhibited, wherein the
bispecific includes a portion which binds to an antigen on the
cell.
42. The method of claim 41, wherein the antigen is a tumor
antigen.
43. The method of claim 42, wherein the tumor antigen is from a
cancer cell selected from the group of cancers consisting of
ovarian cancer, breast cancer, testicular cancer, prostate cancer,
leukemia, and lymphoma.
44. The method of claim 41, wherein the antigen is an
autoantigen.
45. The method of claim 41, wherein the antigen is from a
microorganism.
46. The method of claim 45, wherein the microorganism is selected
from the group consisting of a bacterium, a virus, and a
parasite.
47. A method of treating or preventing a disease characterized by
precipitation of IgA-immune complexes, comprising administering to
a subject in need of treatment an isolated human monoclonal
antibody that specifically binds to CD89 in an amount effective to
treat or prevent the disease, wherein the monoclonal antibody
blocks IgA binding to CD89.
48. The method of claim 47, wherein the disease characterized by
precipitation of IgA-immune complexes is selected from the group
consisting of chronic hepatitis, Henoch-Schonlein purpura (HSP),
Berger's disease, and IgA-glomerulonephritis.
49. The method of claim 47, wherein the monoclonal antibody binds
to the epitope on CD89 defined by the antibody 8.2.
50. A method of detecting the presence of CD89 or a cell expressing
CD89 in a sample, comprising: contacting the sample with the
antibody of claim 1 under conditions that allow for formation of a
complex between the antibody and CD89; and detecting the formation
of the complex.
51. An expression vector comprising a nucleotide sequence encoding
the variable and constant regions of the heavy and light chains of
a human monoclonal antibody which binds to human CD89, wherein the
heavy chain nucleotide sequence is selected from the group
consisting of SEQ ID NO: 1 and SEQ ID NO: 5 and the light chain
nucleotide sequence is selected from the group consisting of SEQ ID
NO: 3 and SEQ ID NO: 7.
Description
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 60/268,075 filed on Feb. 12, 2001, and U.S.
Provisional Application No. 60/338,956 filed on Nov. 5, 2001, both
of which are incorporated herein in their entirety by this
reference.
BACKGROUND OF THE INVENTION
[0002] Receptors for the Fc portions of immunoglobulins are
important in triggering many of the protective functions of
monocytes, macrophages and polymorphonuclear cells. Receptors for
IgG (Fc.gamma. receptors or Fc.gamma.R) on these cells have been
extensively investigated and monoclonal antibodies against these
receptors have been generated and shown to be therapeutically
effective (See e.g. European Patent No. 255 249 entitled
"Monoclonal Antibodies to Fc Receptor for Immunoglobulin G on Human
Mononuclear Phagocytes").
[0003] IgA receptors (Fc.alpha. receptor or CD89) are also capable
of promoting effector cell function. Binding of ligand to CD89
triggers phagocytosis and antibody mediated cell cytotoxicity in
leukocytes and CD89-bearing cell lines. CD89 can also cooperate
with receptors for IgG on effector cells in enhancing the
phagocytosis of target cells.
[0004] CD89 is a receptor which binds to the Fc portion of IgA, the
most abundant Ig in the human body (Kerr, M. A. 1990, Biochem. J.
271:285-296). CD89 is constitutively expressed primarily on
cytotoxic immune effector cells including polymorphonuclear
leukocytes (PMN), monocytes, macrophages, neutrophils and
eosinophils. (Morton, H. C., et al., 1996 Critical Reviews in
Immunology 16:423). CD89 expression on a sub-population of
lymphocytes (Morton, H. C., et al., 1996 Critical Reviews in
Immunology 16:423), and on glomerular mesangial cells also has been
reported (Gomez-Guerrero, C., et al., 1996 J. Immunol.
156:4369-4376). Moreover, CD89 expression on monocytes and PMN can
be enhanced by TNF-.alpha. (Gesl, A., et al., 1994 Scad. J.
Immunol. 39:151-156; Hostoffer, R. W., et al., 1994, The J.
Infectious Diseases 170:82-87), IL-1, GM-CSF, LPS or phorbol esters
(Shen L., et al., J. Immunol. 152:4080-4086; Schiller, C. A. et
al., 1994, Immunology, 81:598-604), whereas IFN-.gamma. and
TGF-.beta.1 decrease Fc.alpha.RI expression (Reterink, T. J. F., et
al., 1996, Clin. Exp. Immunol. 103:161-166).
[0005] The .alpha.-chain of human CD89 is a heavily glycosylated,
type one transmembrane molecule belonging to the Ig super-gene
family which also includes receptors for IgG and IgE. One gene
located on chromosome 19 encodes several alternatively spliced
isoforms of the Fc.alpha.RI alpha chain (55-110 kDa; Morton, H. C.,
et al., 1996 Critical Reviews in Immunology 16:423). Myelocytic
CD89 has been shown to be associated with the FcR .gamma.-chain
which is implicated as playing a role in CD89 signal transduction
(Morton, H. C. et al. 1995, J. Biol. Chem. 270:29781; Pfefferkorn,
L. C., et al. 1995, J. Immunol., 153:3228-3236, Saito, K. et al.,
1995, J. Allergy Clin. Immunol. 96:1152).
[0006] CD89 binds both antigen-complexed and monomeric IgA1 and
IgA2 (Mazangera, R. L. et al., 1990 Biochem. J. 272:159-165),
consistent with the receptor being saturated in vivo with monomeric
IgA in the same manner as Fc.gamma.R and Fc.epsilon.RI are
saturated with IgG and IgE respectively. Cross-linking CD89 on
myeloid effector cells, by polymeric IgA, IgA immune complexes, or
mAb specific for epitopes within or outside the ligand binding
domain, stimulates degranulation, superoxide release, secretion of
inflammatory cytokines, endocytosis and phagocytosis (Patty, C., A.
Herbelin, A. Lihuen, J. F. Bach, and R. C. Monteiro. 1995
Immunology. 86:1-5; Stewart, W. W., R. L. Maz Yegera, L. Shen, and
M. A. Kerr. 1994 J. Leucocyte Biology. 56:481-487; Stewart, W. W.,
and M. A. Kerr. 1990. Immunology. 71:328-334; Shen, L. 1992. J.
Leukocyte Biology. 51:373-378.). These physiological responses
triggered via CD89 can be important in the first line of humoral
defense on mucosal surfaces (Morton, H. C., M. van Egmond, and J.
G. J. van de Winkel. 1996 Critical Reviews in Immunology.
16:423).
SUMMARY OF THE INVENTION
[0007] The present invention provides improved immunotherapeutic
agents for exploiting the therapeutic capacity of human CD89, a
cytotoxic trigger molecule. In particular, the invention provides
isolated human monoclonal antibodies which bind to human CD89, as
well as therapeutic compositions, bispecific antibodies and
molecular complexes containing such antibodies.
[0008] In a particular embodiment of the invention, the antibody is
not inhibited by IgA, e.g., it binds to CD89 at a site different
from the IgA binding site. In another embodiment, the antibody
inhibits IgA binding to CD89, e.g., it binds to CD89 at a site
which is within or near the IgA binding site.
[0009] In another particular embodiment of the invention, the
antibody has the added benefit of not activating complement in vivo
(e.g., not inducing complement mediated lysis of target cells)
which reduces adverse side-effects during treatment. In still
another embodiment, the antibody triggers at least one Fc
receptor-mediated effector cell activity, such as phagocytosis or
secretion of superoxide anion.
[0010] In another particular embodiment of the invention, the
antibody is an IgG1 (e.g., IgG1k) antibody, e.g., having an IgG1
heavy chain and a kappa light chain. Other antibody isotypes also
encompassed by the invention include IgG2, IgG3, IgG4, IgM, IgA1,
IgA2, IgAsec, IgD, and IgE. The antibodies can be whole antibodies
or antigen-binding fragments of the antibodies, including Fab,
F(ab').sub.2, Fv and chain Fv fragments.
[0011] In another particular embodiment of the invention, the
antibody is encoded by human IgG heavy chain and human kappa light
chain nucleic acids comprising nucleotide sequences in their
variable regions as set forth in SEQ ID NOs: 1 or 5 and SEQ ID NOs:
3 or 7, respectively, and conservative sequence modifications
thereof. In another embodiment, the human antibody includes IgG
heavy chain and kappa light chain variable regions which comprise
the amino acid sequences shown in SEQ ID NOs: 2 or 6 and SEQ ID
NOs: 4 or 8, respectively, and conservative sequence modifications
thereof.
[0012] Particular antibodies of the present invention include, for
example, human monoclonal antibodies (mAbs) 14.1, 7.4, and 8.2
(also referred to as 14A8, 7F12, and 8D2, respectively), or an
antibody that binds to the same epitope as (e.g., competes with) or
has the same functional binding characteristics as antibody 14.1,
7.4 or 8.2.
[0013] Human antibodies of the invention can be produced
recombinantly in a host cell (e.g., a CHO cell or a lymphocytic
cell) or be obtained directly from a hybridoma which expresses the
antibody (i.e., which includes a B cell obtained from a transgenic
non-human animal, e.g., a transgenic mouse, having a genome
comprising a human heavy chain transgene and a human light chain
transgene that encode the antibody, fused to an immortalized
cell).
[0014] In another particular embodiment of the invention, the human
antibody of the present invention can be characterized by one or
more of the following properties:
[0015] (a) binding specificity for human CD89;
[0016] (b) a binding equilibrium association constant (Ka) to human
CD89 of at least about 10.sup.7 M.sup.-1;
[0017] (c) a dissociation constant (Kd) from human CD89 of about
10.sup.-8 S.sup.-1 or less;
[0018] (c) absence of complement activation upon in vivo binding to
CD89;
[0019] (d) binding to human CD89 at a site which does not inhibit
human IgA binding;
[0020] (e) a heavy chain comprising the amino acid sequence shown
in SEQ ID NOs: 2 or 6 and conservative sequence modifications
thereof, and a light chain comprising the amino acid sequence shown
in SEQ ID NOs: 4 or 8 and conservative sequence modifications
thereof.
[0021] In another aspect, the present invention provides nucleic
acid molecules encoding the human monoclonal antibodies, or
antigen-binding portions thereof. Recombinant expression vectors
which include nucleic acids encoding antibodies of the invention,
and host cells transfected with such vectors, are also encompassed
by the invention, as are methods of making the antibodies of the
invention by culturing such host cells, e.g., an expression vector
comprising a nucleotide sequence encoding the variable and constant
regions of the heavy and light chains of mAbs 14.1, 7.4 or 8.2.
[0022] In yet another aspect, the invention provides isolated
B-cells from a transgenic non-human animal, e.g., a transgenic
mouse, which express human anti-CD89 antibodies of the invention.
Preferably, the isolated B cells are obtained from a transgenic
non-human animal, e.g., a transgenic mouse, which has been
immunized with a purified or enriched preparation of CD89 antigen
and/or cells expressing CD89. Preferably, the transgenic non-human
animal, e.g., a transgenic mouse, has a genome comprising a human
heavy chain transgene and a human light chain transgene encoding
all or a portion of an antibody of the invention. The isolated
B-cells are then immortalized to provide a source (e.g., a
hybridoma) of human anti-CD89 antibodies.
[0023] Accordingly, the present invention also provides a hybridoma
capable of producing human monoclonal antibodies of the invention
that specifically bind to CD89. In one embodiment, the hybridoma
includes a B cell obtained from a transgenic non-human animal,
e.g., a transgenic mouse having a genome comprising a human heavy
chain transgene and a human light chain transgene encoding all or a
portion of an antibody of the invention, fused to an immortalized
cell. Particular hybridomas of the invention include 14.1, 7.4, and
8.2.
[0024] In yet another aspect, the invention provides a transgenic
non-human animal, such as a transgenic mouse (also referred to
herein as a "HuMab"), which express human monoclonal antibodies
that specifically bind to CD89. In a particular embodiment, the
transgenic non-human animal is a transgenic mouse having a genome
comprising a human heavy chain transgene and a human light chain
transgene encoding all or a portion of an antibody of the
invention. The transgenic non-human animal can be immunized with a
purified or enriched preparation of CD89 antigen and/or cells
expressing CD89. Preferably, the transgenic non-human animal, e.g.,
the transgenic mouse, is capable of producing multiple isotypes of
human monoclonal antibodies to CD89 (e.g., IgG, IgA and/or IgM) by
undergoing V-D-J recombination and isotype switching. Isotype
switching may occur by, e.g., classical or non-classical isotype
switching.
[0025] In another aspect, the present invention provides methods
for producing human monoclonal antibodies which specifically react
with CD89. In one embodiment, the method includes immunizing a
transgenic non-human animal, e.g., a transgenic mouse, having a
genome comprising a human heavy chain transgene and a human light
chain transgene encoding all or a portion of an antibody of the
invention, with a purified or enriched preparation of CD89 antigen
and/or cells expressing CD89. B cells (e.g., splenic B cells) of
the animal are then obtained and fused with myeloma cells to form
immortal, hybridoma cells that secrete human monoclonal antibodies
against CD89.
[0026] In yet another aspect, human anti-CD89 antibodies of the
invention are derivatized, linked to or co-expressed with another
functional molecule, e.g., another peptide or protein (e.g.,
antibody or antibody fragment, such as an Fab' fragment). For
example, an antibody or antigen-binding portion of the invention
can be functionally linked (e.g., by chemical coupling, genetic
fusion, noncovalent association or otherwise) to one or more other
molecular entities, such as another antibody (e.g., to produce a
bispecific or a multispecific antibody), a cytoxin, a cellular
ligand or an antigen. Bispecific and multispecific antibodies of
the present invention are useful for targeting a cell expressing
CD89, e.g., an effector cell, to a selected antigen, such as an
epitope on a tumor cell, an autoantibody producing cell, a pathogen
infected cell, or any other undesirable cell, thereby resulting in
cytolysis or phagocytosis of the cell or pathogen associated with
the antigen. Other target antigens include soluble antigens or
complexes of antigens and microorganisms, e.g., viruses, parasites,
and bacteria.
[0027] Multispecific molecules of the invention also include
trispecific, tetraspecific and other multispecific molecules. In
one embodiment the multispecific molecule includes an
anti-enhancement factor (EF) portion, e.g., a molecule which binds
to a surface protein involved in cytotoxic activity.
[0028] Accordingly, present invention encompasses a large variety
of antibody conjugates, bi- and multispecific molecules, and fusion
proteins, all of which bind to CD89 expressing cells and which
target other molecules to the cells, or which bind to CD89 and to
other molecules or cells.
[0029] In another aspect, the present invention provides a
conjugate comprising a human anti-CD89 antibody of the invention
linked to a therapeutic moiety, e.g., a cytotoxic drug, an
enzymatically active toxin, or a fragment thereof, a radioisotope,
or a small molecule anti-cancer drug.
[0030] Alternatively, human antibodies of the invention can be
co-administered with such therapeutic and cytotoxic agents, but not
linked to them. They can be coadministered simultaneously with such
agents (e.g., in a single composition or separately) or can be
administered before or after administration of such agents. Such
agents can include cytokines, such as G-CSF, GM-CSF, IL-2 or
IFN-alpha, and chemotherapeutic agents such as doxorubicin
(adriarnycin), cisplatin bleomycin sulfate, carmustine,
chlorambucil, and cyclophosphamide hydroxyurea. Human antibodies of
the invention also can be administered in conjunction with
radiation therapy.
[0031] In another aspect, the present invention provides
compositions, e.g., pharmaceutical and diagnostic
compositions/kits, comprising a pharmaceutically acceptable carrier
and at least one human monoclonal antibody of the invention, or an
antigen-binding portion thereof, which specifically binds to CD89.
In one embodiment, the composition comprises a combination of the
human antibodies or antigen-binding portions thereof, preferably
each of which binds to a distinct epitope. Compositions, e.g.,
pharmaceutical compositions, comprising a combination of at least
one human monoclonal antibody of the invention, or antigen-binding
portions thereof, and at least one bispecific or multispecific
molecule of the invention, are also within the scope of the
invention.
[0032] For use in in vivo treatment and prevention of diseases
related to CD89 expression (e.g., over-expression), human
antibodies of the invention are administered to patients (e.g.,
human subjects) at therapeutically effective dosages using any
suitable route of administration, such as injection and other
routes of administration known in the art for antibody-based
clinical products.
[0033] Human antibodies of the present invention can also be used
to modulate CD89 levels on effector cells such as by capping and
elimination of receptors on the cell surface. Mixtures of anti-Fc
receptors can also be used for this purpose.
[0034] In another embodiment, human antibodies of the present
invention which block or inhibit IgA binding to CD89 are useful in
the treatment of diseases characterized by circulating
IgA-containing complexes and/or precipitation of IgA-immune
complexes, e.g., chronic hepatitis, Henoch-Schonlein purpura (HSP),
IgA nephropathy (Berger's disease), or IgA-glomerulonephritis. A
human antibody of the invention can be administered to a patient
suffering from such a disease to inhibit or downregulate the
binding of endogenous IgA to CD89 in vivo.
[0035] Based on their ability to bind both CD89 bearing immune
cells and specific target cells (i.e., cells whose elimination
would be beneficial for the host), bispecific and multispecific
molecules of the present can be used in the treatment of a wide
variety of diseases. Such diseases include, but are not limited to,
autoimmune diseases and cancers (e.g., bladder, breast, colon,
kidney, ovarian, testicular, prostate, lung, brain, rectum,
pancreas, liver, central nervous system, head and neck, kidney,
bone, blood, and lymphatic system), pathogenic infections such as
viral (e.g., HIV, HTLV, and FELV), protozoan (e.g., Toxoplasma
gondii), fungal (e.g., Candida albicans), and bacterial (e.g.,
Staphylococcus aureus, Streptococcus hemolyticus, and Mycobacterium
tuberculsis). Another aspect of the invention provides molecules
that are useful for vaccination against diseases and cancer by
including an antigen from disease organisms, from infected cells,
from gene products of disease organisms or from cancer cells. For
these purposes, the invention provides compositions which are
binding agents that link the useful operative antigen to a binding
determinant that directs the antigen to the immune system.
[0036] In one embodiment, the patient is additionally treated with
a chemotherapeutic agent, radiation, or an agent that modulates,
e.g., enhances or inhibits, the expression or activity of an Fc
receptor, e.g., an Fc.alpha. receptor or an Fc.gamma. receptor,
such as a cytokine. Typical cytokines for administration during
treatment include granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
interferon-.gamma. (IFN-.gamma.), and tumor necrosis factor (TNF).
Typical therapeutic agents include, among others, anti-neoplastic
agents such as doxorubicin (adriamycin), cisplatin bleomycin
sulfate, carmustine, chlorambucil, and cyclophosphamide
hydroxyurea.
[0037] In yet another aspect, the present invention provides a
method for detecting in vitro or in vivo the presence of CD89 in a
sample, e.g., for diagnosing a CD89-related disease. In one
embodiment, this is achieved by contacting a sample to be tested,
optionally along with a control sample, with a human monoclonal
antibody of the invention (or an antigen-binding portion thereof)
under conditions that allow for formation of a complex between the
antibody and CD89. Complex formation is then detected (e.g., using
an ELISA). When using a control sample along with the test sample,
complex is detected in both samples and any statistically
significant difference in the formation of complexes between the
samples is indicative the presence of CD89 in the test sample.
[0038] Other features and advantages of the instant invention be
apparent from the following detailed description and examples which
should not be construed as limiting. The contents of all
references, patents and published patent applications cited
throughout this application are expressly incorporated herein by
reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0039] FIG. 1 shows the nucleotide sequence and corresponding amino
acid sequence of the V.sub.H-region from HuMAb 14.1. CDR regions
are also delineated. The germline segments utilized for the HuMAb
14.1 V.sub.H-region include V.sub.H 3-30.3, D 6-13, and JH4b.
[0040] FIG. 2 shows the nucleotide sequence and corresponding amino
acid sequence of the V.sub.K-region from HuMAb 14.1. CDR regions
are also delineated. The germline segments utilized for the HuMAb
14.1 V.sub.K-region include V.sub.K L18 and JK3.
[0041] FIG. 3 shows the nucleotide sequence and corresponding amino
acid sequence of the V.sub.H-region from HuMAb 8D2. CDR regions are
also delineated. The germline segments utilized for the HuMAb 8D2
V.sub.H-region include V.sub.H 3-30.3, D 7-27, and JH3b.
[0042] FIG. 4 shows the nucleotide sequence and corresponding amino
acid sequence of the V.sub.K-region from HuMAb 8D2. CDR regions are
also delineated. The germline segments utilized for the HuMAb 8D2
V.sub.K-region include V.sub.K A27 and JK2.
DETAILED DESCRIPTION OF THE INVENTION
[0043] The present invention provides isolated human monoclonal
antibodies, including antigen-binding portions thereof, which bind
to an epitope present on a human IgA receptor (CD89). In one
embodiment, the human antibodies are produced in a non-human
transgenic animal, e.g., a transgenic mouse, capable of producing
multiple isotypes of human monoclonal antibodies to CD89 (e.g.,
IgG, IgA and/or IgE) by undergoing V-D-J recombination and isotype
switching. Accordingly, particular aspects of the invention include
not only antibodies, antibody fragments, and pharmaceutical
compositions thereof, but also non-human transgenic animals,
B-cells and hybridomas which produce monoclonal antibodies. Methods
of using the antibodies of the invention to detect a cell
expressing CD89 or to trigger effector functions in a cell
expressing CD89 (for example by crosslinking CD89 molecules using a
bispecific antibody comprising an anti-CD89 antibody of the
invention and another antibody directed against an antigen on a
target cell), either in vitro or in vivo, are also encompassed by
the invention. Methods of using the antibodies of the invention to
block or inhibit IgA binding to CD89 are also provided and are
useful in the treatment of diseases characterized by abnormal
endogenous IgA, such as diseases characterized by circulating
IgA-containing complexes and/or precipitation of IgA-immune
complexes, e.g., chronic hepatitis, Henoch-Schonlein purpura (HSP),
IgA nephropathy (Berger's disease), or IgA-glomerulonephritis.
[0044] In order that the present invention may be more readily
understood, certain terms are first defined. Additional definitions
are set forth throughout the detailed description.
[0045] As used herein, the terms "CD89," "human IgA receptor," and
"Fc-alpha receptor" (Fc.alpha.RI) are used interchangeably and are
intended to include the gene product of one .alpha.-gene
(Fc.alpha.RI) located on chromosome 19. This gene is known to
encode several alternatively spliced transmembrane isoforms of 55
to 110 kDa. Fc.alpha.RI (CD89) is constitutively expressed on
monocytes/macrophages, eosinophilic and neutrophilic granulocytes,
but not on non-effector cell populations. Fc.alpha.RI has medium
affinity (.apprxeq.5.times.10.sup.7 M.sup.-1) for both IgA1 and
IgA2, which is increased upon exposure to cytokines such as G-CSF
or GM-CSF (Morton, H. C. et al. (1996) Critical Reviews in
Immunology 16:423-440). Fc.alpha.RI receptors are preferred trigger
receptors for use in the invention because they are (1) expressed
primarily on immune effector cells, e.g., monocytes, macrophages,
neutrophils and eosinophils; (2) expressed at high levels (e.g.,
5,000-100,000 per cell); (3) mediators of cytotoxic activities
(e.g., ADCC, phagocytosis); (4) mediate enhanced antigen
presentation of antigens, including self-antigens, targeted to
them.
[0046] As used herein, the term "effector cell" refers to an immune
cell which is involved in the effector phase of an immune response,
as opposed to the cognitive and activation phases of an immune
response. Exemplary immune cells include a cell of a myeloid or
lymphoid origin, e.g., lymphocytes (e.g., B cells and T cells
including cytolytic T cells (CTLs)), killer cells, natural killer
cells, macrophages, monocytes, eosinophils, neutrophils,
polymorphonuclear cells, granulocytes, mast cells, and basophils.
Some effector cells express specific Fc receptors and carry out
specific immune functions. In preferred embodiments, an effector
cell is capable of inducing antibody-dependent cell-mediated
cytotoxicity (ADCC), e.g., a neutrophil capable of inducing ADCC.
For example, monocytes, macrophages, which express FcR are involved
in specific killing of target cells and presenting antigens to
other components of the immune system, or binding to cells that
present antigens. In other embodiments, an effector cell can
phagocytose a target antigen, target cell, or microorganism. The
expression of a particular FcR on an effector cell can be regulated
by humoral factors such as cytokines. For example, expression of
Fc.alpha.RI has been found to be up-regulated by G-CSF or GM-CSF.
This enhanced expression increases the effector function of
Fc.alpha.RI-bearing cells against targets. An effector cell can
phagocytose or lyse a target antigen or a target cell.
[0047] "Target cell" shall mean any undesirable cell in a subject
(e.g., a human or animal) that can be targeted by a composition
(e.g., a human monoclonal antibody, a bispecific, or a
multispecific molecule) of the invention. In one embodiment, the
target cell is a cell expressing or overexpressing CD89. In another
embodiment, target cells include tumor cells. Tumor cells that can
be targeted are tumor cells of any type of cancer, including cancer
of breast, ovarian, prostate, testicular, lung, colon, rectum,
pancreas, liver, central nervous system, kidney, head, neck, bone,
blood, and lymphatic system. In addition to tumor cells, the
effector cell can be targeted against auto-antibody producing
lymphocytes for treatment of autoimmune disease or an IgE-producing
lymphocyte for treatment of allergy. The target can also be
microorganism (bacterium or virus) or a soluble antigen (such as
rheumatoid factor, or other auto-antibodies and toxins). A
microorganism is intended to include pathogens, e.g., viruses,
bacteria, fungi, protozoa.
[0048] The term "antigen" means any natural or synthetic
immunogenic substance, a fragment or portion of an immunogenic
substance, a peptide epitope, or a hapten. The term "antigen" also
includes substances which are nonimmunogenic in uncomplexed form,
but are immunogenic when complexed. The term "uncomplexed" includes
substances which are not linked to form a molecular complex of the
present invention. The term "complexed" includes substances which
are linked to form a molecular complex of the present
invention.
[0049] As used herein, the term "inhibits growth" (e.g., referring
to cells) is intended to include any measurable decrease in the
growth of a cell when contacted with an anti-CD89 antibody as
compared to the growth of the same cell not in contact with an
anti-CD89 antibody, e.g., the inhibition of growth of a cell by at
least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or
100%.
[0050] As used herein, the terms "inhibits binding" and "blocks
binding" (e.g., referring to inhibition/blocking of binding of CD89
ligand, e.g., IgA, to CD89) are used interchangeably and encompass
both partial and complete inhibition/blocking. The
inhibition/blocking of IgA to CD89 preferably reduces or alters the
normal level or type of effector cell functions that occurs when
IgA binds to CD89 without inhibition or blocking. Inhibition and
blocking are also intended to include any measurable decrease in
the binding affinity of IgA to CD89 when in contact with an
anti-CD89 antibody as compared to the ligand not in contact with an
anti-CD89 antibody, e.g., the blocking of CD89 ligands to CD89 by
at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or
100%.
[0051] The term "antibody" as referred to herein includes whole
antibodies and any antigen binding fragment (i.e., "antigen-binding
portion") or single chain thereof. An "antibody" refers to a
glycoprotein comprising at least two heavy (H) chains and two light
(L) chains inter-connected by disulfide bonds, or an antigen
binding portion thereof. Each heavy chain is comprised of a heavy
chain variable region (abbreviated herein as VH) and a heavy chain
constant region. The heavy chain constant region is comprised of
three domains, CH1, CH2 and CH3. Each light chain is comprised of a
light chain variable region (abbreviated herein as VL) and a light
chain constant region. The light chain constant region is comprised
of one domain, CL. The VH and VL regions can be further subdivided
into regions of hypervariability, termed complementarity
determining regions (CDR), interspersed with regions that are more
conserved, termed framework regions (FR). Each VH and VL is
composed of three CDRs and four FRs, arranged from amino-terminus
to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2,
FR3, CDR3, FR4. The variable regions of the heavy and light chains
contain a binding domain that interacts with an antigen. The
constant regions of the antibodies may mediate the binding of the
immunoglobulin to host tissues or factors, including various cells
of the immune system (e.g., effector cells) and the first component
(C1q) of the classical complement system.
[0052] The term "antigen-binding portion" of an antibody (or simply
"antibody portion"), as used herein, refers to one or more
fragments of an antibody that retain the ability to specifically
bind to an antigen (e.g., CD89). It has been shown that the
antigen-binding function of an antibody can be performed by
fragments of a full-length antibody. Examples of binding fragments
encompassed within the term "antigen-binding portion" of an
antibody include (i) a Fab fragment, a monovalent fragment
consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab').sub.2
fragment, a bivalent fragment comprising two Fab fragments linked
by a disulfide bridge at the hinge region; (iii) a Fd fragment
consisting of the VH and CHI domains; (iv) a Fv fragment consisting
of the VL and VH domains of a single arm of an antibody, (v) a dAb
fragment (Ward et al., (1989) Nature 341:544-546), which consists
of a VH domain; and (vi) an isolated complementarity determining
region (CDR). Furthermore, although the two domains of the Fv
fragment, VL and VH, are coded for by separate genes, they can be
joined, using recombinant methods, by a synthetic linker that
enables them to be made as a single protein chain in which the VL
and VH regions pair to form monovalent molecules (known as single
chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426;
and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
Such single chain antibodies are also intended to be encompassed
within the term "antigen-binding portion" of an antibody. These
antibody fragments are obtained using conventional techniques known
to those with skill in the art, and the fragments are screened for
utility in the same manner as are intact antibodies.
[0053] The term "epitope" means a protein determinant capable of
specific binding to an antibody. Epitopes usually consist of
chemically active surface groupings of molecules such as amino
acids or sugar side chains and usually have specific three
dimensional structural characteristics, as well as specific charge
characteristics. Conformational and nonconformational epitopes are
distinguished in that the binding to the former but not the latter
is lost in the presence of denaturing solvents.
[0054] The term "bispecific molecule" is intended to include any
agent, e.g., a protein, peptide, or protein or peptide complex,
which has two different binding specificities. For example, the
molecule may bind to, or interact with, (a) a cell surface antigen
and (b) an Fc receptor on the surface of an effector cell, e.g.,
CD89. The term "multispecific molecule" or "heterospecific
molecule" is intended to include any agent, e.g., a protein,
peptide, or protein or peptide complex, which has more than two
different binding specificities. For example, the molecule may bind
to, or interact with, (a) a cell surface antigen, (b) an Fe
receptor on the surface of an effector cell, and (c) at least one
other component. Accordingly, the invention includes, but is not
limited to, bispecific, trispecific, tetraspecific, and other
multispecific molecules which are directed to cell surface
antigens, such as CD89, and to other targets, such as Fc receptors
on effector cells.
[0055] The term "bispecific antibodies" also includes diabodies.
Diabodies are bivalent, bispecific antibodies in which the VH and
VL domains are expressed on a single polypeptide chain, but using a
linker that is too short to allow for pairing between the two
domains on the same chain, thereby forcing the domains to pair with
complementary domains of another chain and creating two antigen
binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl.
Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure
2:1121-1123).
[0056] As used herein, the term "heteroantibodies" refers to two or
more antibodies, antibody binding fragments (e.g., Fab),
derivatives therefrom, or antigen binding regions linked together,
at least two of which have different specificities. These different
specificities include a binding specificity for an Fc receptor on
an effector cell, and a binding specificity for an antigen or
epitope on a target cell, e.g., a tumor cell.
[0057] The term "human antibody", as used herein, is intended to
include antibodies having variable and constant regions derived
from human germline immunoglobulin sequences. The human antibodies
of the invention may include amino acid residues not encoded by
human germline immunoglobulin sequences (e.g., mutations introduced
by random or site-specific mutagenesis in vitro or by somatic
mutation in vivo). However, the term "human antibody", as used
herein, is not intended to include antibodies in which CDR
sequences derived from the germline of another mammalian species,
such as a mouse, have been grafted onto human framework
sequences.
[0058] The terms "monoclonal antibody" or "monoclonal antibody
composition" as used herein refer to a preparation of antibody
molecules of single molecular composition. A monoclonal antibody
composition displays a single binding specificity and affinity for
a particular epitope. Accordingly, the term "human monoclonal
antibody" refers to antibodies displaying a single binding
specificity which have variable and constant regions derived from
human germline immunoglobulin sequences. In one embodiment, the
human monoclonal antibodies are produced by a hybridoma which
includes a B cell obtained from a transgenic non-human animal,
e.g., a transgenic mouse, having a genome comprising a human heavy
chain transgene and a light chain transgene fused to an
immortalized cell.
[0059] The term "recombinant human antibody", as used herein, is
intended to include all human antibodies that are prepared,
expressed, created or isolated by recombinant means, such as (a)
antibodies isolated from an animal (e.g., a mouse) that is
transgenic for human immunoglobulin genes (described further in
Section I, below), (b) antibodies expressed using a recombinant
expression vector transfected into a host cell, (c) antibodies
isolated from a recombinant, combinatorial human antibody library,
and (c) antibodies prepared, expressed, created or isolated by any
other means that involve splicing of human immunoglobulin gene
sequences to other DNA sequences. Such recombinant human antibodies
have variable and constant regions derived from human germline
immunoglobulin sequences. In certain embodiments, however, such
recombinant human antibodies can be subjected to in vitro
mutagenesis (or, when an animal transgenic for human Ig sequences
is used, in vivo somatic mutagenesis) and thus the amino acid
sequences of the VH and VL regions of the recombinant antibodies
are sequences that, while derived from and related to human
germline VH and VL sequences, may not naturally exist within the
human antibody germline repertoire in vivo.
[0060] As used herein, a "heterologous antibody" is defined in
relation to the transgenic non-human organism producing such an
antibody. This term refers to an antibody having an amino acid
sequence or an encoding nucleic acid sequence corresponding to that
found in an organism not consisting of the transgenic non-human
animal, and generally from a species other than that of the
transgenic non-human animal.
[0061] As used herein, a "heterohybrid antibody" refers to an
antibody having a light and heavy chains of different organismal
origins. For example, an antibody having a human heavy chain
associated with a murine light chain is a heterohybrid antibody.
Examples of heterohybrid antibodies include chimeric and humanized
antibodies, discussed supra.
[0062] An "isolated antibody," as used herein, is intended to refer
to an antibody which is substantially free of other antibodies
having different antigenic specificities (e.g., an isolated
antibody that specifically binds to CD89 is substantially free of
antibodies that specifically bind antigens other than CD89). An
isolated antibody that specifically binds to an epitope, isoform or
variant of human CD89 may, however, have cross-reactivity to other
related antigens, e.g., from other species (e.g., CD89 species
homologs). Moreover, an isolated antibody may be substantially free
of other cellular material and/or chemicals. In one embodiment of
the invention, a combination of "isolated" monoclonal antibodies
having different specificities are combined in a well defined
composition.
[0063] As used herein, "specific binding" refers to antibody
binding to a predetermined antigen. Typically, the antibody binds
with an affinity of at least about 1.times.10.sup.7 M.sup.-1, and
binds to the predetermined antigen with an affinity that is at
least two-fold greater than its affinity for binding to a
non-specific antigen (e.g., BSA, casein) other than the
predetermined antigen or a closely-related antigen. The phrases "an
antibody recognizing an antigen" and "an antibody specific for an
antigen" are used interchangeably herein with the term "an antibody
which binds specifically to an antigen".
[0064] As used herein, the term "high affinity" for an IgG antibody
refers to a binding affinity of at least about 10.sup.7M.sup.-1,
preferably at least about 10.sup.8M.sup.-1, more preferably at
least about 10.sup.9M.sup.-1, 10.sup.10M.sup.-1, 10.sup.11M.sup.-1
or greater, e.g., up to 10.sup.13M.sup.-1 or greater. However,
"high affinity" binding can vary for other antibody isotypes. For
example, "high affinity" binding for an IgM isotype refers to a
binding affinity of at least about 1.times.10.sup.7M.sup.-1.
[0065] The term "K.sub.assoc" or "K.sub.a" as used herein, is
intended to refer to the association constant of a particular
antibody-antigen interaction.
[0066] The term "K.sub.dis" or "K.sub.d", as used herein, is
intended to refer to the dissociation constant of a particular
antibody-antigen interaction.
[0067] As used herein, "isotype" refers to the antibody class
(e.g., IgM or IgG1) that is encoded by heavy chain constant region
genes.
[0068] As used herein, "isotype switching" refers to the phenomenon
by which the class, or isotype, of an antibody changes from one Ig
class to one of the other Ig classes.
[0069] As used herein, "nonswitched isotype" refers to the isotypic
class of heavy chain that is produced when no isotype switching has
taken place; the CH gene encoding the nonswitched isotype is
typically the first C.sub.H gene immediately downstream from the
functionally rearranged VDJ gene. Isotype switching has been
classified as classical or non-classical isotype switching.
Classical isotype switching occurs by recombination events which
involve at least one switch sequence region in the transgene.
Non-classical isotype switching may occur by, for example,
homologous recombination between human .sigma..sub..mu. and human
.SIGMA..sub..mu. (.delta.-associated deletion). Alternative
non-classical switching mechanisms, such as intertransgene and/or
interchromosomal recombination, among others, may occur and
effectuate isotype switching.
[0070] As used herein, the term "switch sequence" refers to those
DNA sequences responsible for switch recombination. A "switch
donor" sequence, typically a .mu. switch region, will be 5' (i.e.,
upstream) of the construct region to be deleted during the switch
recombination. The "switch acceptor" region will be between the
construct region to be deleted and the replacement constant region
(e.g., .gamma., .epsilon., etc.). As there is no specific site
where recombination always occurs, the final gene sequence will
typically not be predictable from the construct.
[0071] As used herein, "glycosylation pattern" is defined as the
pattern of carbohydrate units that are covalently attached to a
protein, more specifically to an immunoglobulin protein. A
glycosylation pattern of a heterologous antibody can be
characterized as being substantially similar to glycosylation
patterns which occur naturally on antibodies produced by the
species of the nonhuman transgenic animal, when one of ordinary
skill in the art would recognize the glycosylation pattern of the
heterologous antibody as being more similar to said pattern of
glycosylation in the species of the nonhuman transgenic animal than
to the species from which the C.sub.H genes of the transgene were
derived.
[0072] The term "naturally-occurring" as used herein as applied to
an object refers to the fact that an object can be found in nature.
For example, a polypeptide or polynucleotide sequence that is
present in an organism (including viruses) that can be isolated
from a source in nature and which has not been intentionally
modified by man in the laboratory is naturally-occurring.
[0073] The term "rearranged" as used herein refers to a
configuration of a heavy chain or light chain immunoglobulin locus
wherein a V segment is positioned immediately adjacent to a D-J or
J segment in a conformation encoding essentially a complete VH or
VL domain, respectively. A rearranged immunoglobulin gene locus can
be identified by comparison to germline DNA; a rearranged locus
will have at least one recombined heptamer/nonamer homology
element.
[0074] The term "unrearranged" or "germline configuration" as used
herein in reference to a V segment refers to the configuration
wherein the V segment is not recombined so as to be immediately
adjacent to a D or J segment.
[0075] The term "nucleic acid molecule", as used herein, is
intended to include DNA molecules and RNA molecules. A nucleic acid
molecule may be single-stranded or double-stranded, but preferably
is double-stranded DNA.
[0076] The term "isolated nucleic acid molecule," as used herein in
reference to nucleic acids encoding antibodies or antibody portions
(e.g., VH, VL, CDR3) that bind to CD89, is intended to refer to a
nucleic acid molecule in which the nucleotide sequences encoding
the antibody or antibody portion are free of other nucleotide
sequences encoding antibodies or antibody portions that bind
antigens other than CD89, which other sequences may naturally flank
the nucleic acid in human genomic DNA. In one embodiment, the human
anti-CD89 antibody, or portion thereof, includes the nucleotide or
amino acid sequence of 14.1, 7.4, 8.2, as well as heavy chain (VH)
and light chain (VL) variable regions having the sequences shown in
SEQ ID NOs: 1, 3, 5, 7, and 2, 4, 6, 8, respectively.
[0077] As disclosed and claimed herein, the sequences set forth in
SEQ ID NOs: 1-8 include "conservative sequence modifications",
i.e., nucleotide and amino acid sequence modifications which do not
significantly affect or alter the binding characteristics of the
antibody encoded by the nucleotide sequence or containing the amino
acid sequence. Such conservative sequence modifications include
nucleotide and amino acid substitutions, additions and deletions.
Modifications can be introduced into SEQ ID NOs: 1-8 by standard
techniques known in the art, such as site-directed mutagenesis and
PCR-mediated mutagenesis. Conservative amino acid substitutions
include ones in which the amino acid residue is replaced with an
amino acid residue having a similar side chain. Families of amino
acid residues having similar side chains have been defined in the
art. These families include amino acids with basic side chains
(e.g., lysine, arginine, histidine), acidic side chains (e.g.,
aspartic acid, glutamic acid), uncharged polar side chains (e.g.,
glycine, asparagine, glutamine, serine, threonine, tyrosine,
cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine,
leucine, isoleucine, proline, phenylalanine, methionine),
beta-branched side chains (e.g., threonine, valine, isoleucine) and
aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,
histidine). Thus, a predicted nonessential amino acid residue in a
human anti-CD89 antibody is preferably replaced with another amino
acid residue from the same side chain family.
[0078] Alternatively, in another embodiment, mutations can be
introduced randomly along all or part of a anti-CD89 antibody
coding sequence, such as by saturation mutagenesis, and the
resulting modified anti-CD89 antibodies can be screened for binding
activity.
[0079] Accordingly, antibodies encoded by the (heavy and light
chain variable region) nucleotide sequences disclosed herein (i.e.,
SEQ ID NOs: 1, 3, 5, and 7) and/or containing the (heavy and light
chain variable region) amino acid sequences disclosed herein (i.e.,
SEQ ID NOs: 2, 4, 6, and 8) include substantially similar
antibodies encoded by or containing similar sequences which have
been conservatively modified. Further discussion as to how such
substantially similar antibodies can be generated based on the
partial (i.e., heavy and light chain variable regions) sequences
disclosed herein as SEQ ID NOs: 1-8 is provided below.
[0080] For nucleic acids, the term "substantial homology" indicates
that two nucleic acids, or designated sequences thereof, when
optimally aligned and compared, are identical, with appropriate
nucleotide insertions or deletions, in at least about 80% of the
nucleotides, usually at least about 90% to 95%, and more preferably
at least about 98% to 99.5% of the nucleotides. Alternatively,
substantial homology exists when the segments will hybridize under
selective hybridization conditions, to the complement of the
strand.
[0081] The percent identity between two sequences is a function of
the number of identical positions shared by the sequences (i.e., %
homology=# of identical positions/total # of positions.times.100),
taking into account the number of gaps, and the length of each gap,
which need to be introduced for optimal alignment of the two
sequences. The comparison of sequences and determination of percent
identity between two sequences can be accomplished using a
mathematical algorithm, as described in the non-limiting examples
below.
[0082] The percent identity between two nucleotide sequences can be
determined using the GAP program in the GCG software package
(available at http://www.gcg.com), using a NWSgapdna.CMP matrix and
a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2,
3, 4, 5, or 6. The percent identity between two nucleotide or amino
acid sequences can also determined using the algorithm of E. Meyers
and W. Miller (Comput. Appl. Biosci., 4:11-17 (1988)) which has
been incorporated into the ALIGN program (version 2.0), using a
PAM120 weight residue table, a gap length penalty of 12 and a gap
penalty of 4. In addition, the percent identity between two amino
acid sequences can be determined using the Needleman and Wunsch (J.
Mol. Biol. 48:444-453 (1970)) algorithm which has been incorporated
into the GAP program in the GCG software package (available at
http://www.gcg.com), using either a Blossum 62 matrix or a PAM250
matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length
weight of 1, 2, 3, 4, 5, or 6.
[0083] The nucleic acid and protein sequences of the present
invention can further be used as a "query sequence" to perform a
search against public databases to, for example, identify related
sequences. Such searches can be performed using the NBLAST and
XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol.
Biol. 215:403-10. BLAST nucleotide searches can be performed with
the NBLAST program, score=100, wordlength=12 to obtain nucleotide
sequences homologous to the nucleic acid molecules of the
invention. BLAST protein searches can be performed with the XBLAST
program, score=50, wordlength=3 to obtain amino acid sequences
homologous to the protein molecules of the invention. To obtain
gapped alignments for comparison purposes, Gapped BLAST can be
utilized as described in Altschul et al., (1997) Nucleic Acids Res.
25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs,
the default parameters of the respective programs (e.g., XBLAST and
NBLAST) can be used. See http://www.ncbi.nlm.nih.gov.
[0084] The nucleic acids may be present in whole cells, in a cell
lysate, or in a partially purified or substantially pure form. A
nucleic acid is "isolated" or "rendered substantially pure" when
purified away from other cellular components or other contaminants,
e.g., other cellular nucleic acids or proteins, by standard
techniques, including alkaline/SDS treatment, CsCl banding, column
chromatography, agarose gel electrophoresis and others well known
in the art. See, F. Ausubel, et al., ed. Current Protocols in
Molecular Biology, Greene Publishing and Wiley Interscience, New
York (1987).
[0085] The nucleic acid compositions of the present invention,
while often in a native sequence (except for modified restriction
sites and the like), from either cDNA, genomic or mixtures may be
mutated, thereof in accordance with standard techniques to provide
gene sequences. For coding sequences, these mutations, may affect
amino acid sequence as desired. In particular, DNA sequences
substantially homologous to or derived from native V, D, J,
constant, switches and other such sequences described herein are
contemplated (where "derived" indicates that a sequence is
identical or modified from another sequence).
[0086] A nucleic acid is "operably linked" when it is placed into a
functional relationship with another nucleic acid sequence. For
instance, a promoter or enhancer is operably linked to a coding
sequence if it affects the transcription of the sequence. With
respect to transcription regulatory sequences, operably linked
means that the DNA sequences being linked are contiguous and, where
necessary to join two protein coding regions, contiguous and in
reading frame. For switch sequences, operably linked indicates that
the sequences are capable of effecting switch recombination.
[0087] The term "vector," as used herein, is intended to refer to a
nucleic acid molecule capable of transporting another nucleic acid
to which it has been linked. One type of vector is a "plasmid",
which refers to a circular double stranded DNA loop into which
additional DNA segments may be ligated. Another type of vector is a
viral vector, wherein additional DNA segments may be ligated into
the viral genome. Certain vectors are capable of autonomous
replication in a host cell into which they are introduced (e.g.,
bacterial vectors having a bacterial origin of replication and
episomal mammalian vectors). Other vectors (e.g., non-episomal
mammalian vectors) can be integrated into the genome of a host cell
upon introduction into the host cell, and thereby are replicated
along with the host genome. Moreover, certain vectors are capable
of directing the expression of genes to which they are operatively
linked. Such vectors are referred to herein as "recombinant
expression vectors" (or simply, "expression vectors"). In general,
expression vectors of utility in recombinant DNA techniques are
often in the form of plasmids. In the present specification,
"plasmid" and "vector" may be used interchangeably as the plasmid
is the most commonly used form of vector. However, the invention is
intended to include such other forms of expression vectors, such as
viral vectors (e.g., replication defective retroviruses,
adenoviruses and adeno-associated viruses), which serve equivalent
functions.
[0088] The term "recombinant host cell" (or simply "host cell"), as
used herein, is intended to refer to a cell into which a
recombinant expression vector has been introduced. It should be
understood that such terms are intended to refer not only to the
particular subject cell but to the progeny of such a cell. Because
certain modifications may occur in succeeding generations due to
either mutation or environmental influences, such progeny may not,
in fact, be identical to the parent cell, but are still included
within the scope of the term "host cell" as used herein.
Recombinant host cells include, for example, CHO cells and
lymphocytic cells.
[0089] Various aspects of the invention are described in further
detail in the following subsections.
[0090] I. Production of Human Antibodies to CD89
[0091] The monoclonal antibodies (mAbs) of the invention can be
produced by a variety of techniques, including conventional
monoclonal antibody methodology e.g., the standard somatic cell
hybridization technique of Kohler and Milstein (1975) Nature 256:
495. Although somatic cell hybridization procedures are preferred,
in principle, other techniques for producing monoclonal antibody
can be employed e.g., viral or oncogenic transformation of B
lymphocytes.
[0092] The preferred animal system for preparing hybridomas is the
murine system. Hybridoma production in the mouse is a very
well-established procedure. Immunization protocols and techniques
for isolation of immunized splenocytes for fusion are known in the
art. Fusion partners (e.g., murine myeloma cells) and fusion
procedures are also known.
[0093] In a preferred embodiment, human monoclonal antibodies
directed against CD89 can be generated using transgenic mice
carrying parts of the human immune system rather than the mouse
system. These transgenic mice, referred to herein as "HuMab" mice,
contain a human immunoglobulin gene miniloci that encodes
unrearranged human heavy (.mu. and .gamma.) and .kappa. light chain
immunoglobulin sequences, together with targeted mutations that
inactivate the endogenous .mu. and .kappa. chain loci (Lonberg, et
al. (1994) Nature 368(6474): 856-859). Accordingly, the mice
exhibit reduced expression of mouse IgM or .kappa., and in response
to immunization, the introduced human heavy and light chain
transgenes undergo class switching and somatic mutation to generate
high affinity human IgG.kappa. monoclonal (Lonberg, N. et al.
(1994), supra; reviewed in Lonberg, N. (1994) Handbook of
Experimental Pharmacology 113:49-101; Lonberg, N. and Huszar, D.
(1995) Intern. Rev. Immunol. Vol. 13: 65-93, and Harding, F. and
Lonberg, N. (1995) Ann. N.Y. Acad. Sci 764:536-546). The
preparation of HuMab mice is described in detail Section II below
and in Taylor, L. et al. (1992) Nucleic Acids Research
20:6287-6295; Chen, J. et al. (1993) International Immunology 5:
647-656; Tuaillon et al. (1993) Proc. Natl. Acad. Sci USA
90:3720-3724; Choi et al. (1993) Nature Genetics 4:117-123; Chen,
J. et al. (1993) EMBO J. 12: 821-830; Tuaillon et al. (1994) J.
Immunol. 152:2912-2920; Lonberg et al., (1994) Nature 368(6474):
856-859; Lonberg, N. (1994) Handbook of Experimental Pharmacology
113:49-101; Taylor, L. et al. (1994) International Immunology 6:
579-591; Lonberg, N. and Huszar, D. (1995) Intern. Rev. Immunol.
Vol. 13: 65-93; Harding, F. and Lonberg, N. (1995) Ann. N.Y. Acad.
Sci 764:536-546; Fishwild, D. et al. (1996) Nature Biotechnology
14: 845-851, the contents of all of which are hereby incorporated
by reference in their entirety. See further, U.S. Pat. Nos.
5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397;
5,661,016; 5,814,318; 5,874,299; and 5,770,429; all to Lonberg and
Kay, and GenPharm International; U.S. Pat. No. 5,545,807 to Surani
et al.; International Publication Nos. WO 98/24884, published on
Jun. 11, 1998; WO 94/25585, published Nov. 10, 1994; WO 93/1227,
published Jun. 24, 1993; WO 92/22645, published Dec. 23, 1992; WO
92/03918, published Mar. 19, 1992, the disclosures of all of which
are hereby incorporated by reference in their entity.
Alternatively, the HCO12 transgenic mice described in Example 2,
can be used to generate human anti-CD89 antibodies.
[0094] HuMab Immunizations
[0095] To generate fully human monoclonal antibodies to CD89, HuMab
mice can be immunized with a purified or enriched preparation of
CD89 antigen and/or cells expressing CD89, as described by Lonberg,
N. et al. (1994) Nature 368(6474): 856-859; Fishwild, D. et al.
(1996) Nature Biotechnology 14: 845-851 and WO 98/24884.
Preferably, the mice will be 6-16 weeks of age upon the first
infusion. For example, a purified or enriched preparation (5-20
.mu.g) of CD89 antigen (e.g., purified from CD89-expressing LNCaP
cells) can be used to immunize the HuMab mice intraperitoneally. In
the event that immunizations using a purified or enriched
preparation of CD89 antigen do not result in antibodies, mice can
also be immunized with cells expressing CD89, e.g., a tumor cell
line, to promote immune responses.
[0096] Cumulative experience with various antigens has shown that
the HuMab transgenic mice respond best when initially immunized
intraperitoneally (IP) with antigen in complete Freund's adjuvant,
followed by every other week i.p. immunizations (up to a total of
6) with antigen in incomplete Freund's adjuvant. The immune
response can be monitored over the course of the immunization
protocol with plasma samples being obtained by retroorbital bleeds.
The plasma can be screened by ELISA (as described below), and mice
with sufficient titers of anti-CD89 human immunoglobulin can be
used for fusions. Mice can be boosted intravenously with antigen 3
days before sacrifice and removal of the spleen. It is expected
that 2-3 fusions for each antigen may need to be performed. Several
mice will be immunized for each antigen. For example, a total of
twelve HuMab mice of the HC07 and HC012 strains can be
immunized.
[0097] Generation of Hybridomas Producing Human Monoclonal
Antibodies to CD89
[0098] The mouse splenocytes can be isolated and fused with PEG to
a mouse myeloma cell line based upon standard protocols. The
resulting hybridomas are then screened for the production of
antigen-specific antibodies. For example, single cell suspensions
of splenic lymphocytes from immunized mice are fused to one-sixth
the number of P3X63-Ag8.653 nonsecreting mouse myeloma cells (ATCC,
CRL 1580) with 50% PEG. Cells are plated at approximately
2.times.10.sup.5 in flat bottom microtiter plate, followed by a two
week incubation in selective medium containing 20% fetal Clone
Serum, 18% "653" conditioned media, 5% origen (IGEN), 4 mM
L-glutamine, 1 mM L.about.glutamine, 1 mM sodium pyruvate, 5 mM
HEPES, 0.055 mM 2-mercaptoethanol, 50 units/ml penicillin, 50 mg/ml
streptomycin, 50 mg/ml gentamycin and 1.times.HAT (Sigma; the HAT
is added 24 hours after the fusion). After two weeks, cells are
cultured in medium in which the HAT is replaced with HT. Individual
wells are then screened by ELISA for human anti-CD89 monoclonal IgM
and IgG antibodies. Once extensive hybridoma growth occurs, medium
is observed usually after 10-14 days. The antibody secreting
hybridomas are replated, screened again, and if still positive for
human IgG, anti-CD89 monoclonal antibodies, can be subcloned at
least twice by limiting dilution. The stable subclones are then
cultured in vitro to generate small amounts of antibody in tissue
culture medium for characterization.
[0099] Use of Partial Antibody Sequences to Express Intact
Antibodies
[0100] Antibodies interact with target antigens predominantly
through amino acid residues that are located in the six heavy and
light chain complementarity determining regions (CDRs). For this
reason, the amino acid sequences within CDRs are more diverse
between individual antibodies than sequences outside of CDRs.
Because CDR sequences are responsible for most antibody-antigen
interactions, it is possible to express recombinant antibodies that
mimic the properties of specific naturally occurring antibodies by
constructing expression vectors that include CDR sequences from the
specific naturally occurring antibody grafted onto framework
sequences from a different antibody with different properties (see,
e.g., Riechmann, L. et al., 1998, Nature 332:323-327; Jones, P. et
al., 1986, Nature 321:522-525; and Queen, C. et al., 1989, Proc.
Natl. Acad. See. U.S.A. 86:10029-10033). Such framework sequences
can be obtained from public DNA databases that include germline
antibody gene sequences. These germline sequences will differ from
mature antibody gene sequences because they will not include
completely assembled variable genes, which are formed by V(D)J
joining during B cell maturation. Germline gene sequences will also
differ from the sequences of a high affinity secondary repertoire
antibody at individual evenly across the variable region. For
example, somatic mutations are relatively infrequent in the
amino-terminal portion of framework region. For example, somatic
mutations are relatively infrequent in the amino terminal portion
of framework region 1 and in the carboxy-terminal portion of
framework region 4. Furthermore, many somatic mutations do not
significantly alter the binding properties of the antibody. For
this reason, it is not necessary to obtain the entire DNA sequence
of a particular antibody in order to recreate an intact recombinant
antibody having binding properties similar to those of the original
antibody (see PCT/US99/05535 filed on Mar. 12, 1999, which is
herein incorporated by referenced for all purposes). Partial heavy
and light chain sequence spanning the CDR regions is typically
sufficient for this purpose. The partial sequence is used to
determine which germline variable and joining gene segments
contributed to the recombined antibody variable genes. The germline
sequence is then used to fill in missing portions of the variable
regions. Heavy and light chain leader sequences are cleaved during
protein maturation and do not contribute to the properties of the
final antibody. For this reason, it is necessary to use the
corresponding germline leader sequence for expression constructs.
To add missing sequences, cloned cDNA sequences cab be combined
with synthetic oligonucleotides by ligation or PCR amplification.
Alternatively, the entire variable region can be synthesized as a
set of short, overlapping, oligonucleotides and combined by PCR
amplification to create an entirely synthetic variable region
clone. This process has certain advantages such as elimination or
inclusion or particular restriction sites, or optimization of
particular codons.
[0101] The nucleotide sequences of heavy and light chain
transcripts from a hybridomas are used to design an overlapping set
of synthetic oligonucleotides to create synthetic V sequences with
identical amino acid coding capacities as the natural sequences.
The synthetic heavy and kappa chain sequences can differ from the
natural sequences in three ways: strings of repeated nucleotide
bases are interrupted to facilitate oligonucleotide synthesis and
PCR amplification; optimal translation initiation sites are
incorporated according to Kozak's rules (Kozak, 1991, J. Biol.
Chem. 266L19867019870); and, HindIII sites are engineered upstream
of the translation initiation sites.
[0102] For both the heavy and light chain variable regions, the
optimized coding, and corresponding non-coding, strand sequences
are broken down into 30-50 nucleotide approximately the midpoint of
the corresponding non-coding oligonucleotide. Thus, for each chain,
the oligonucleotides can be assemble into overlapping double
stranded sets that span segments of 150-400 nucleotides. The pools
are then used as templates to produce PCR amplification products of
150-400 nucleotides. Typically, a single variable region
oligonucleotide set will be broken down into two pools which are
separately amplified to generate two overlapping PCV products.
These overlapping products are then combined by PCT amplification
to form the complete variable region. It may also be desirable to
include an overlapping fragment of the heavy or light chain
constant region (including the BbsI site of the kappa light chain,
or the AgeI site if the gamma heavy chain) in the PCR amplification
to generate fragments that can easily be cloned into the expression
vector constructs.
[0103] The reconstructed heavy and light chain variable regions are
then combined with cloned promoter, translation initiation,
constant region, 3' untranslated, polyadenylation, and
transcription termination, sequences to form expression vector
constructs. The heavy and light chain expression constructs can be
combined into a single vector, co-transfected, serially
transfected, or separately transfected into host cells which are
then fused to form a host cell expressing both chains.
[0104] Plasmids for use in construction of expression vectors for
human IgG.kappa. are described below. The plasmids were constructed
so that PCR amplified V heavy and V kappa light chain cDNA
sequences could be used to reconstruct complete heavy and light
chain minigenes. These plasmids can be used to express completely
human, or chimeric IgG.sub.1.kappa. or IgG.sub.4.kappa. antibodies.
Similar plasmids can be constructed for expression of other heavy
chain isotypes, or for expression of antibodies comprising lambda
light chains.
[0105] Thus, in another aspect of the invention, the structural
features of an human anti-CD89 antibodies of the invention, 14.1,
7.4, or 8.2, are used to create structurally related human
anti-CD89 antibodies that retain at least one functional property
of the antibodies of the invention, such as binding to CD89. More
specifically, one or more CDR regions of 14.1, 7.4, or 8.2 can be
combined recombinantly with known human framework regions and CDRs
to create additional, recombinantly-engineered, human anti-CD89
antibodies of the invention.
[0106] Accordingly, in another embodiment, the invention provides a
method for preparing an anti-CD89 antibody comprising:
[0107] preparing an antibody comprising (1) human heavy chain
framework regions and human heavy chain CDRs, wherein at least one
of the human heavy chain CDRs comprises an amino acid sequence
selected from the amino acid sequences of CDRs shown in FIG. 1 or 3
(or corresponding amino acid residues in SEQ ID NOs: 2 or 6); and
(2) human light chain framework regions and human light chain CDRs,
wherein at least one of the human light chain CDRs comprises an
amino acid sequence selected from the amino acid sequences of CDRs
shown in FIG. 2 or 4 (or corresponding amino acid residues in SEQ
ID NOs: 4 or 8);
[0108] wherein the antibody retains the ability to bind to CD89.
The ability of the antibody to bind CD89 can be determined using
standard binding assays, such as those set forth in the Examples
(e.g., an ELISA).
[0109] Since it is well known in the art that antibody heavy and
light chain CDR3 domains play a particularly important role in the
binding specificity/affinity of an antibody for an antigen, the
recombinant antibodies of the invention prepared as set forth above
preferably comprise the heavy and light chain CDR3s of 14.1, 7.4,
or 8.2. The antibodies further can comprise the CDR2s of 14.1, 7.4,
or 8.2. The antibodies further can comprise the CDR1s of 14.1, 7.4,
or 8.2. Accordingly, the invention further provides anti-CD89
antibodies comprising: (1) human heavy chain framework regions, a
human heavy chain CDR1 region, a human heavy chain CDR2 region, and
a human heavy chain CDR3 region, wherein the human heavy chain CDR3
region is selected from the CDR3s of 14.1, 7.4, and 8.2 as shown in
FIG. 1 or 3 (or corresponding amino acid residues in SEQ ID NOs: 2
or 6); and (2) human light chain framework regions, a human light
chain CDR1 region, a human light chain CDR2 region, and a human
light chain CDR3 region, wherein the human light chain CDR3 region
is selected from the CDR3s of 14.1, 7.4, and 8.2 as shown in FIGS.
2 and 4 (or corresponding amino acid residues in SEQ ID NOs: 4 or
8), wherein the antibody binds CD89. The antibody may further
comprise the heavy chain CDR2 and/or the light chain CDR2 of 14.1,
7.4, or 8.2. The antibody may further comprise the heavy chain CDR1
and/or the light chain CDR1 of 14.1, 7.4, or 8.2.
[0110] Preferably, the CDR1, 2, and/or 3 of the engineered
antibodies described above comprise the exact amino acid
sequence(s) as those of 14.1, 7.4, or 8.2 disclosed herein.
However, the ordinarily skilled artisan will appreciate that some
deviation from the exact CDR sequences of 14.1, 7.4, and 8.2 may be
possible while still retaining the ability of the antibody to bind
CD89 effectively (e.g., conservative substitutions). Accordingly,
in another embodiment, the engineered antibody may be composed of
one or more CDRs that are, for example, 90%, 95%, 98% or 99.5%
identical to one or more CDRs of 14.1, 7.4, or 8.2.
[0111] In addition to simply binding CD89, engineered antibodies
such as those described above may be selected for their retention
of other functional properties of antibodies of the invention, such
as:
[0112] 1) binding to live cells expressing CD89;
[0113] 2) high affinity binding to CD89;
[0114] 3) binding to a unique epitope on CD89 (to eliminate the
possibility that monoclonal antibodies with complimentary
activities when used in combination would compete for binding to
the same epitope;
[0115] 4) opsonization of cells expressing CD89; and/or
[0116] 5) mediation of growth inhibition, phagocytosis and/or
killing of cells expressing CD89 in the presence of human effector
cells.
[0117] Characterization of Binding of Human Monoclonal Antibodies
to CD89
[0118] To characterize binding of human monoclonal CD89 antibodies
of the invention, sera from immunized mice can be tested, for
example, by ELISA. In a typical (but non-limiting) example of an
ELISA protocol, microtiter plates are coated with purified CD89 at
0.25 .mu.g/ml in PBS, and then blocked with 5% bovine serum albumin
in PBS. Dilutions of plasma from CD89-immunized mice are added to
each well and incubated for 1-2 hours at 37.degree. C. The plates
are washed with PBS/Tween and then incubated with a goat-anti-human
IgG Fc-specific polyclonal reagent conjugated to alkaline
phosphatase for 1 hour at 37.degree. C. After washing, the plates
are developed with pNPP substrate (1 mg/ml), and analyzed at OD of
405-650. Preferably, mice which develop the highest titers will be
used for fusions.
[0119] An ELISA assay as described above can also be used to screen
for hybridomas that show positive reactivity with CD89 immunogen.
Hybridomas that bind with high avidity to CD89 will be subcloned
and further characterized. One clone from each hybridoma, which
retains the reactivity of the parent cells (by ELISA), can be
chosen for making a 5-10 vial cell bank stored at -140.degree. C.,
and for antibody purification.
[0120] To purify human anti-CD89 antibodies, selected hybridomas
can be grown in two-liter spinner-flasks for monoclonal antibody
purification. Supernatants can be filtered and concentrated before
affinity chromatography with protein A-sepharose (Pharmacia,
Piscataway, N.J.). Eluted IgG can be checked by gel electrophoresis
and high performance liquid chromatography to ensure purity. The
buffer solution can be exchanged into PBS, and the concentration
can be determined by OD.sub.280 using 1.43 extinction coefficient.
The monoclonal antibodies can be aliquoted and stored at
-80.degree. C.
[0121] To determine if the selected human anti-CD89 monoclonal
antibodies bind to unique epitopes, each antibody can be
biotinylated using commercially available reagents (Pierce,
Rockford, Ill.). Competition studies using unlabeled monoclonal
antibodies and biotinylated monoclonal antibodies can be performed
using CD89 coated-ELISA plates as described above. Biotinylated mAb
binding can be detected with a strep-avidin-alkaline phosphatase
probe.
[0122] To determine the isotype of purified antibodies, isotype
ELISAs can be performed. For example, wells of microtiter plates
can be coated with 10 .mu.g/ml of anti-human Ig overnight at
4.degree. C. After blocking with 5% BSA, the plates are reacted
with 10 .mu.g/ml of monoclonal antibodies or purified isotype
controls, at ambient temperature for two hours. The wells can then
be reacted with either human IgG1 or human IgM-specific alkaline
phosphatase-conjugated probes. Plates are developed and analyzed as
described above.
[0123] In order to demonstrate binding of monoclonal antibodies to
live cells expressing the CD89, flow cytometry can be used. In a
typical (but non-limiting) example of a flow cytometry protocol,
cell lines expressing CD89 (grown under standard growth conditions)
are mixed with various concentrations of monoclonal antibodies in
PBS containing 0.1% Tween 80 and 20% mouse serum, and incubated at
37.degree. C. for 1 hour. After washing, the cells are reacted with
Fluorescein-labeled anti-human IgG antibody under the same
conditions as the primary antibody staining. The samples can be
analyzed by FACScan instrument using light and side scatter
properties to gate on single cells. An alternative assay using
fluorescence microscopy may be used (in addition to or instead of)
the flow cytometry assay. Cells can be stained exactly as described
above and examined by fluorescence microscopy. This method allows
visualization of individual cells, but may have diminished
sensitivity depending on the density of the antigen.
[0124] Anti-CD89 human IgGs can be further tested for reactivity
with CD89antigen by Western blotting. For example, cell extracts
from cells expressing CD89 can be prepared and subjected to sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. After
electrophoresis, the separated antigens will be transferred to
nitrocellulose membranes, blocked with 20% mouse serum, and probed
with the monoclonal antibodies to be tested. Human IgG binding can
be detected using anti-human IgG alkaline phosphatase and developed
with BCIP/NBT substrate tablets (Sigma Chem. Co., St. Louis,
Mo.).
[0125] II. Production of Transgenic Nonhuman Animals Which Generate
Human Monoclonal Anti-CD89 Antibodies
[0126] In yet another aspect, the invention provides transgenic
non-human animals, e.g., a transgenic mice, which are capable of
expressing human monoclonal antibodies that specifically bind to
CD89, preferably with high affinity. In a preferred embodiment, the
transgenic non-human animals, e.g., the transgenic mice (HuMab
mice), have a genome comprising a human heavy chain transgene and a
light chain transgene. In one embodiment, the transgenic non-human
animals, e.g., the transgenic mice, have been immunized with a
purified or enriched preparation of CD89 antigen and/or cells
expressing CD89. Preferably, the transgenic non-human animals,
e.g., the transgenic mice, are capable of producing multiple
isotypes of human monoclonal antibodies to CD89 (e.g., IgG, IgA
and/or IgE) by undergoing V-D-J recombination and isotype
switching. Isotype switching may occur by, e.g., classical or
non-classical isotype switching.
[0127] The design of a transgenic non-human animal that responds to
foreign antigen stimulation with a heterologous antibody
repertoire, requires that the heterologous immunoglobulin
transgenes contain within the transgenic animal function correctly
throughout the pathway of B-cell development. In a preferred
embodiment, correct function of a heterologous heavy chain
transgene includes isotype switching. Accordingly, the transgenes
of the invention are constructed so as to produce isotype switching
and one or more of the following: (1) high level and cell-type
specific expression, (2) functional gene rearrangement, (3)
activation of and response to allelic exclusion, (4) expression of
a sufficient primary repertoire, (5) signal transduction, (6)
somatic hypermutation, and (7) domination of the transgene antibody
locus during the immune response.
[0128] Not all of the foregoing criteria need be met. For example,
in those embodiments wherein the endogenous immunoglobulin loci of
the transgenic animal are functionally disrupted, the transgene
need not activate allelic exclusion. Further, in those embodiments
wherein the transgene comprises a functionally rearranged heavy
and/or light chain immunoglobulin gene, the second criteria of
functional gene rearrangement is unnecessary, at least for that
transgene which is already rearranged. For background on molecular
immunology, see, Fundamental Immunology, 2nd edition (1989), Paul
William E., ed. Raven Press, N.Y., which is incorporated herein by
reference.
[0129] In certain embodiments, the transgenic non-human animals
used to generate the human monoclonal antibodies of the invention
contain rearranged, unrearranged or a combination of rearranged and
unrearranged heterologous immunoglobulin heavy and light chain
transgenes in the germline of the transgenic animal. Each of the
heavy chain transgenes comprises at least one C.sub.H gene. In
addition, the heavy chain transgene may contain functional isotype
switch sequences, which are capable of supporting isotype switching
of a heterologous transgene encoding multiple C.sub.H genes in the
B-cells of the transgenic animal. Such switch sequences may be
those which occur naturally in the germline immunoglobulin locus
from the species that serves as the source of the transgene C.sub.H
genes, or such switch sequences may be derived from those which
occur in the species that is to receive the transgene construct
(the transgenic animal). For example, a human transgene construct
that is used to produce a transgenic mouse may produce a higher
frequency of isotype switching events if it incorporates switch
sequences similar to those that occur naturally in the mouse heavy
chain locus, as presumably the mouse switch sequences are optimized
to function with the mouse switch recombinase enzyme system,
whereas the human switch sequences are not. Switch sequences may be
isolated and cloned by conventional cloning methods, or may be
synthesized de novo from overlapping synthetic oligonucleotides
designed on the basis of published sequence information relating to
immunoglobulin switch region sequences (Mills et al., Nucl. Acids
Res. 15:7305-7316 (1991); Sideras et al., Intl. Immunol. 1:631-642
(1989), which are incorporated herein by reference).
[0130] For each of the foregoing transgenic animals, functionally
rearranged heterologous heavy and light chain immunoglobulin
transgenes are found in a significant fraction of the B-cells of
the transgenic animal (at least 10 percent).
[0131] The transgenes used to generate the transgenic animals of
the invention include a heavy chain transgene comprising DNA
encoding at least one variable gene segment, one diversity gene
segment, one joining gene segment and at least one constant region
gene segment. The immunoglobulin light chain transgene comprises
DNA encoding at least one variable gene segment, one joining gene
segment and at least one constant region gene segment. The gene
segments encoding the light and heavy chain gene segments are
heterologous to the transgenic non-human animal in that they are
derived from, or correspond to, DNA encoding immunoglobulin heavy
and light chain gene segments from a species not consisting of the
transgenic non-human animal. In one aspect of the invention, the
transgene is constructed such that the individual gene segments are
unrearranged, i.e., not rearranged so as to encode a functional
immunoglobulin light or heavy chain. Such unrearranged transgenes
support recombination of the V, D, and J gene segments (functional
rearrangement) and preferably support incorporation of all or a
portion of a D region gene segment in the resultant rearranged
immunoglobulin heavy chain within the transgenic non-human animal
when exposed to CD89 antigen.
[0132] In an alternate embodiment, the transgenes comprise an
unrearranged "mini-locus." Such transgenes typically comprise a
substantial portion of the C, D, and J segments as well as a subset
of the V gene segments. In such transgene constructs, the various
regulatory sequences, e.g. promoters, enhancers, class switch
regions, splice-donor and splice-acceptor sequences for RNA
processing, recombination signals and the like, comprise
corresponding sequences derived from the heterologous DNA. Such
regulatory sequences may be incorporated into the transgene from
the same or a related species of the non-human animal used in the
invention. For example, human immunoglobulin gene segments may be
combined in a transgene with a rodent immunoglobulin enhancer
sequence for use in a transgenic mouse. Alternatively, synthetic
regulatory sequences may be incorporated into the transgene,
wherein such synthetic regulatory sequences are not homologous to a
functional DNA sequence that is known to occur naturally in the
genomes of mammals. Synthetic regulatory sequences are designed
according to consensus rules, such as, for example, those
specifying the permissible sequences of a splice-acceptor site or a
promoter/enhancer motif. For example, a minilocus comprises a
portion of the genomic immunoglobulin locus having at least one
internal (i.e., not at a terminus of the portion) deletion of a
non-essential DNA portion (e.g., intervening sequence; intron or
portion thereof) as compared to the naturally-occurring germline Ig
locus.
[0133] In a preferred embodiment of the invention, the transgenic
animal used to generate human antibodies to CD89 contains at least
one, typically 2-10, and sometimes 25-50 or more copies of the
transgene described in Example 12 of WO 98/24884 (e.g., pHC1 or
pHC2) bred with an animal containing a single copy of a light chain
transgene described in Examples 5, 6, 8, or 14 of WO 98/24884, and
the offspring bred with the J.sub.H deleted animal described in
Example 10 of WO 98/24884, the contents of which are hereby
expressly incorporated by reference. Animals are bred to
homozygosity for each of these three traits. Such animals have the
following genotype: a single copy (per haploid set of chromosomes)
of a human heavy chain unrearranged mini-locus (described in
Example 12 of WO 98/24884), a single copy (per haploid set of
chromosomes) of a rearranged human K light chain construct
(described in Example 14 of WO 98/24884), and a deletion at each
endogenous mouse heavy chain locus that removes all of the
functional J.sub.H segments (described in Example 10 of WO
98/24884). Such animals are bred with mice that are homozygous for
the deletion of the J.sub.H segments (Examples 10 of WO 98/24884)
to produce offspring that are homozygous for the J.sub.H deletion
and hemizygous for the human heavy and light chain constructs. The
resultant animals are injected with antigens and used for
production of human monoclonal antibodies against these
antigens.
[0134] B cells isolated from such an animal are monospecific with
regard to the human heavy and light chains because they contain
only a single copy of each gene. Furthermore, they will be
monospecific with regards to human or mouse heavy chains because
both endogenous mouse heavy chain gene copies are nonfunctional by
virtue of the deletion spanning the J.sub.H region introduced as
described in Example 9 and 12 of WO 98/24884. Furthermore, a
substantial fraction of the B cells will be monospecific with
regards to the human or mouse light chains because expression of
the single copy of the rearranged human .kappa. light chain gene
will allelically and isotypically exclude the rearrangement of the
endogenous mouse .kappa. and lambda chain genes in a significant
fraction of B-cells.
[0135] The transgenic mouse of the preferred embodiment will
exhibit immunoglobulin production with a significant repertoire,
ideally substantially similar to that of a native mouse. Thus, for
example, in embodiments where the endogenous Ig genes have been
inactivated, the total immunoglobulin levels will range from about
0.1 to 10 mg/ml of serum, preferably 0.5 to 5 mg/ml, ideally at
least about 1.0 mg/ml. When a transgene capable of effecting a
switch to IgG from IgM has been introduced into the transgenic
mouse, the adult mouse ratio of serum IgG to IgM is preferably
about 10: 1. The IgG to IgM ratio will be much lower in the
immature mouse. In general, greater than about 10%, preferably 40
to 80% of the spleen and lymph node B cells express exclusively
human IgG protein.
[0136] The repertoire will ideally approximate that shown in a
non-transgenic mouse, usually at least about 10% as high,
preferably 25 to 50% or more. Generally, at least about a thousand
different immunoglobulins (ideally IgG), preferably 10.sup.4 to
10.sup.6 or more, will be produced, depending primarily on the
number of different V, J and D regions introduced into the mouse
genome. These immunoglobulins will typically recognize about
one-half or more of highly antigenic proteins, e.g., staphylococcus
protein A. Typically, the immunoglobulins will exhibit an affinity
for preselected antigens of at least about 10.sup.7M.sup.-1,
preferably at least about 10.sup.9M.sup.-1, more preferably at
least about 10.sup.10M.sup.-1, 10.sup.11M.sup.-1,
10.sup.12M.sup.-1, or greater, e.g., up to 10.sup.13M.sup.-1 or
greater.
[0137] In some embodiments, it may be preferable to generate mice
with predetermined repertoires to limit the selection of V genes
represented in the antibody response to a predetermined antigen
type. A heavy chain transgene having a predetermined repertoire may
comprise, for example, human VH genes which are preferentially used
in antibody responses to the predetermined antigen type in humans.
Alternatively, some VH genes may be excluded from a defined
repertoire for various reasons (e.g., have a low likelihood of
encoding high affinity V regions for the predetermined antigen;
have a low propensity to undergo somatic mutation and affinity
sharpening; or are immunogenic to certain humans). Thus, prior to
rearrangement of a transgene containing various heavy or light
chain gene segments, such gene segments may be readily identified,
e.g. by hybridization or DNA sequencing, as being from a species of
organism other than the transgenic animal.
[0138] The transgenic mice of the present invention can be
immunized with a purified or enriched preparation of CD89 antigen
and/or cells expressing CD89 as described previously. The mice will
produce B cells which undergo class-switching via intratransgene
switch recombination (cis-switching) and express immunoglobulins
reactive with CD89. The immunoglobulins can be human sequence
antibodies, wherein the heavy and light chain polypeptides are
encoded by human transgene sequences, which may include sequences
derived by somatic mutation and V region recombinatorial joints, as
well as germline-encoded sequences; these human sequence
immunoglobulins can be referred to as being substantially identical
to a polypeptide sequence encoded by a human V.sub.L or V.sub.H
gene segment and a human J.sub.L or J.sub.L segment, even though
other non-germline sequences may be present as a result of somatic
mutation and differential V-J and V-D-J recombination joints. With
respect to such human sequence antibodies, the variable regions of
each chain are typically at least 80 percent encoded by human
germline V, J, and, in the case of heavy chains, D, gene segments;
frequently at least 85 percent of the variable regions are encoded
by human germline sequences present on the transgene; often 90 or
95 percent or more of the variable region sequences are encoded by
human germline sequences present on the transgene. However, since
non-germline sequences are introduced by somatic mutation and VJ
and VDJ joining, the human sequence antibodies will frequently have
some variable region sequences (and less frequently constant region
sequences) which are not encoded by human V, D, or J gene segments
as found in the human transgene(s) in the germline of the mice.
Typically, such non-germline sequences (or individual nucleotide
positions) will cluster in or near CDRs, or in regions where
somatic mutations are known to cluster.
[0139] The human sequence antibodies which bind to the
predetermined antigen can result from isotype switching, such that
human antibodies comprising a human sequence .gamma. chain (such as
.gamma.1, .gamma.2a, .gamma.2B, or .gamma.3) and a human sequence
light chain (such as K) are produced. Such isotype-switched human
sequence antibodies often contain one or more somatic mutation(s),
typically in the variable region and often in or within about 10
residues of a CDR) as a result of affinity maturation and selection
of B cells by antigen, particularly subsequent to secondary (or
subsequent) antigen challenge. These high affinity human sequence
antibodies may have binding affinities of at least 1.times.10.sup.9
M.sup.-1, typically at least 5.times.10.sup.9 M.sup.-1, frequently
more than 1.times.10.sup.10 M.sup.-1, and sometimes
5.times.10.sup.10 M.sup.-1 to 1.times.10.sup.11 M.sup.-1 or
greater.
[0140] Another aspect of the invention pertains to the B cells from
such mice which can be used to generate hybridomas expressing human
monoclonal antibodies which bind with high affinity (e.g., greater
than 2.times.10.sup.9 M.sup.-1) to CD89. Thus, in another
embodiment of the invention, these hybridomas are used to generate
a composition comprising an immunoglobulin having an affinity
constant (K.sub.a) of at least 2.times.10.sup.9 M.sup.-1 for
binding CD89, wherein said immunoglobulin comprises:
[0141] a human sequence light chain composed of (1) a light chain
variable region having a polypeptide sequence which is
substantially identical to a polypeptide sequence encoded by a
human V.sub.L gene segment and a human J.sub.L segment, and (2) a
light chain constant region having a polypeptide sequence which is
substantially identical to a polypeptide sequence encoded by a
human C.sub.L gene segment; and
[0142] a human sequence heavy chain composed of a (1) a heavy chain
variable region having a polypeptide sequence which is
substantially identical to a polypeptide sequence encoded by a
human V.sub.H gene segment, optionally a D region, and a human
J.sub.H segment, and (2) a constant region having a polypeptide
sequence which is substantially identical to a polypeptide sequence
encoded by a human C.sub.H gene segment.
[0143] The development of high affinity human monoclonal antibodies
against CD89 is facilitated by a method for expanding the
repertoire of human variable region gene segments in a transgenic
mouse having a genome comprising an integrated human immunoglobulin
transgene, said method comprising introducing into the genome a V
gene transgene comprising V region gene segments which are not
present in said integrated human immunoglobulin transgene. Often,
the V region transgene is a yeast artificial chromosome comprising
a portion of a human V.sub.H or V.sub.L (V.sub.K) gene segment
array, as may naturally occur in a human genome or as may be
spliced together separately by recombinant methods, which may
include out-of-order or omitted V gene segments. Often at least
five or more functional V gene segments are contained on the YAC.
In this variation, it is possible to make a transgenic mouse
produced by the V repertoire expansion method, wherein the mouse
expresses an immunoglobulin chain comprising a variable region
sequence encoded by a V region gene segment present on the V region
transgene and a C region encoded on the human Ig transgene. By
means of the V repertoire expansion method, transgenic mice having
at least 5 distinct V genes can be generated; as can mice
containing at least about 24 V genes or more. Some V gene segments
may be non-functional (e g., pseudogenes and the like); these
segments may be retained or may be selectively deleted by
recombinant methods available to the skilled artisan, if
desired.
[0144] Once the mouse germline has been engineered to contain a
functional YAC having an expanded V segment repertoire,
substantially not present in the human Ig transgene containing the
J and C gene segments, the trait can be propagated and bred into
other genetic backgrounds, including backgrounds where the
functional YAC having an expanded V segment repertoire is bred into
a mouse germline having a different human Ig transgene. Multiple
functional YACs having an expanded V segment repertoire may be bred
into a germline to work with a human Ig transgene (or multiple
human Ig transgenes). Although referred to herein as YAC
transgenes, such transgenes when integrated into the genome may
substantially lack yeast sequences, such as sequences required for
autonomous replication in yeast; such sequences may optionally be
removed by genetic engineering (e.g., restriction digestion and
pulsed-field gel electrophoresis or other suitable method) after
replication in yeast in no longer necessary (i.e., prior to
introduction into a mouse ES cell or mouse prozygote). Methods of
propagating the trait of human sequence immunoglobulin expression,
include breeding a transgenic mouse having the human Ig
transgene(s), and optionally also having a functional YAC having an
expanded V segment repertoire. Both V.sub.H and V.sub.L gene
segments may be present on the YAC. The transgenic mouse may be
bred into any background desired by the practitioner, including
backgrounds harboring other human transgenes, including human Ig
transgenes and/or transgenes encoding other human lymphocyte
proteins. The invention also provides a high affinity human
sequence immunoglobulin produced by a transgenic mouse having an
expanded V region repertoire YAC transgene. Although the foregoing
describes a preferred embodiment of the transgenic animal of the
invention, other embodiments are contemplated which have been
classified in four categories:
[0145] I. Transgenic animals containing an unrearranged heavy and
rearranged light immunoglobulin transgene;
[0146] II. Transgenic animals containing an unrearranged heavy and
unrearranged light immunoglobulin transgene;
[0147] III. Transgenic animal containing rearranged heavy and an
unrearranged light immunoglobulin transgene; and
[0148] IV. Transgenic animals containing rearranged heavy and
rearranged light immunoglobulin transgenes.
[0149] Of these categories of transgenic animal, the preferred
order of preference is as follows II>I>III>IV where the
endogenous light chain genes (or at least the K gene) have been
knocked out by homologous recombination (or other method) and
I>II>III>IV where the endogenous light chain genes have
not been knocked out and must be dominated by allelic
exclusion.
[0150] III. Bispecific/Multispecific Molecules Which Bind to
CD89
[0151] In yet another embodiment of the invention, human monoclonal
antibodies to CD89, or antigen-binding portions thereof, can be
derivatized or linked to another functional molecule, e.g., another
peptide or protein (e.g., an Fab' fragment) to generate a
bispecific or multispecific molecule which binds to multiple
binding sites or target epitopes. For example, an antibody or
antigen-binding portion of the invention can be functionally linked
(e.g., by chemical coupling, genetic fusion, noncovalent
association or otherwise) to one or more other binding molecules,
such as another antibody, antibody fragment, peptide or binding
mimetic. The antibody or antibody fragment also can be linked to an
antigen, e.g., a tumor antigen, such that the antigen is targeted
to CD89 expressing immune cells, for example, to enhance the
process if internalization and presentation of the antigen and,
ultimately, to stimulate an immune response.
[0152] Accordingly, the present invention includes bispecific and
multispecific molecules comprising at least one first binding
specificity for CD89 and a second binding specificity for a target
cell, e.g., a target epitope of a tumor cell. Bispecific antibodies
comprising a murine antibody directed against CD89 and a second
antibody directed against a tumor antigen have been demonstrated to
be effective anti-tumor agents. See for example, Valerius, T. et
al. (1997) Blood 90:4485-4492 (describing the anti-tumor activity
of an Fc.alpha.RI.times.HER-2/Neu bispecific antibody used with or
without G-CSF therapy); Elsasser, D. et al. (1999) Anticancer Res.
19:1525-1528 (describing the anti-tumor activity of an
Fc.alpha.RI.times.EGFR bispecific antibody used with or without
G-CSF or GM-CSF therapy); Stockmeyer, B. et al. (2000) J. Immunol.
165:5954-5961 (describing the anti-tumor activity of an
Fc.alpha.RI.times.CD20 bispecific antibody used with or without
G-CSF or GM-CSF therapy); Stockmeyer, B. et al. (2001) J. Immunol.
Methods 248:103-111 (describing the anti-tumor activity of
Fc.alpha.RI.times.CD20 and Fc.alpha.RI.times.HER-2/neu bispecific
antibodies used with or without G-CSF or GM-CSF therapy); and
Sundarapandiyan, K. et al (2001) J. Immunol. Methods 248:113-123
(describing the anti-tumor activity of an Fc.alpha.RI.times.CD30
bispecific antibody). The human anti-CD89 antibodies of the
invention can be used in the same type of bispecific constructs as
anti-tumor agents.
[0153] Tumor cells that can be targeted are tumor cells of any type
of cancer, including cancer of breast, ovarian, prostate,
testicular, lung, colon, rectum, pancreas, liver, central nervous
system, kidney, head, neck, bone, blood, and lymphatic system.
Preferred target antigens include carcinoembryonic antigen (CEA),
gastrin releasing peptide receptor antigen, mucine antigens, EGF-R,
HER2/neu, HER3, HER4, CD20, CD30, MAGE antigens, SART antigens,
MUCI antigen, c-erb-2 antigen and TAG 72. TAG 72 is found, e.g., on
tumors of the breast, colon, and ovary. An antigen binding region
specific for CEA can be, e.g., from the single chain antibody,
termed MFE-23, is described in Casey et al. (1994) J. Immunol.
Methods 179:105 and Chester et al. (1994) Lancet 343:455. An
anti-HER2/neu antibody is produced by the cell line 520C9 (Ring et
al. 1991 J. Immunol. 28: 915-917). Antibody H425 is a humanized
version of anti-EGF-R antibody M425. An antibody for TAG 72 is
monoclonal antibody cc49 described in published PCT application WO
93/11161, published PCT application WO 90/04410, corresponding to
granted EP Patent No. 365 997; published PCT application WO
93/12231; and published PCT application WO 89/01783. Yet other
antigens can be antigens associated with B cell lymphomas, e.g.,
HLA-DR, CD74, CD79, CD20, CD30, CD37, and CD19. Antigens associated
with other blood diseases are also within the scope of the
invention. Accordingly, the invention also provides methods for
treating blood cell disorders, such as leukemias and lymphomas.
[0154] Breast and ovarian cancers can be sex hormone dependent
cancers. Breast tumors may be characterized by abnormally expressed
receptors, e.g. those of the human-EGF-like receptor family (HER),
for example HER-2, -3, and 4. The invention is not limited to these
embodiments of HER antigens. The natural HER ligand, Heregulin, can
be incorporated into a human monoclonal antibody, e.g., bispecific
antibody (BsAb) or multispecific molecule, as a means to target a
breast tumor cell expressing one or more HER receptor during
cancer. Further, heregulin molecules are binding determinants for
heterodimeric HER receptors containing, e.g., a monomer of each of
HER-2, -3 or -4 in combination. In one embodiment, a monoclonal
antibody comprises amino acids 171-239 of the heregulin .beta.2
shown in U.S. Pat. No. 5,367,060. Other portions of heregulin
.beta.2, as well as portions of other heregulin molecules, such as
those disclosed in U.S. Pat. No. 5,367,060 can also be used.
[0155] Antibodies, or antigen-binding portions thereof, of the
invention can also be used for treating tumors of the central
nervous systems. The nestin protein, which is expressed during
normal mammalian fetal development, is expressed on tumors of the
central nervous system, including most forms of brain cancer
(McKay, D. G. Ronald, U.S. Pat. No. 5,338,839, Aug. 16, 1994).
Nestin is also expressed on melanomas on the skin and on melanomas
that have metastasized (V. A. Florenes, R. Holm, O. Myklebost, U.
Lendahl, O. Fodstad, Cancer Res. 54: 354-6, 1994), to other organs
and are difficult to detect and treat. The preferred site of
delivery for treatment of a brain tumor with the molecules of this
invention is directly into the central nervous system or directly,
to the brain via spinal injection or fine needle delivery. For a
metastatic cancer, a preferred delivery route would be by direct
injection into the circulation, or by the ex vivo blood methods
described herein.
[0156] Other tumor types for which the methods of this invention
are exemplified by, but are not limited to, Wilm's tumor (A. J.
Buckler, K. M. Call, T. M. Glaser, D. A. Haber, D. E. Housman, C.
Y. Ito, J. Pelletier, Rose, E. A. Rose, U.S. Pat. No. 5,350,840) a
pediatric kidney cancer due to occurrence of a somatic mutation in
the patient's single copy of a gene normally found in two intact
copies. Wilm's tumor can be cured surgically in 95% of cases, and a
binding agent is envisioned to be suitable as an adjunct
therapeutic modality for surgical patients. Other examples of known
cancer-associated proteins for which the compositions of matter and
methods of the current invention are suitable include those
associated with gastrointestinal cancer (R. Fishel et al.,
International Application WO 95/14085, 05/26/95), those
characterized by development of multiple drug resistance during
chemotherapy (J. M. Croop et al., U.S. Pat. No. 5,198,344), and a
large number of oncogenes well known to the skilled artisan such as
Rb, ras, and c-myc, the sequences of which are available for
analysis to those with skill in the art. The compositions of this
invention are, for example, suitable for inhibition of secreted
enzymes such as matrix metalloproteinases, which are considered to
potentiate tumor metastasis (Liotta, L. A., et al., (1991), Cell,
64:327-336). In the latter embodiment, a binding agent with a
binding determinant to the matrix metalloproteinase and another for
Fc.alpha.R would facilitate inhibition and clearance of these
enzymes from in situ activity. If used in conjunction with standard
surgical and chemotherapeutic regimens, the compositions are
foreseen to reduce cancer re-occurrence and enhance long-term
survival.
[0157] In addition to tumor cells, the effector cell can be
targeted against auto-antibody producing lymphocytes for treatment
of autoimmune disease or an IgE-producing lymphocyte for treatment
of allergy. Autoimmune disorders which can be treated with a
binding agent of the invention include diabetes mellitus, arthritis
(including rheumatoid arthritis, juvenile rheumatoid arthritis,
osteoarthritis, psoriatic arthritis), multiple sclerosis,
myasthenia gravis, systemic lupus erythematosis, autoimmune
thyroiditis, dermatitis (including atopic dermatitis and eczematous
dermatitis), psoriasis, Sjogren's Syndrome, including
keratoconjunctivitis sicca secondary to Sjogren's Syndrome,
alopecia areata, allergic responses due to arthropod bite
reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis,
keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma,
cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis,
drug eruptions, leprosy reversal reactions, erythema nodosum
leprosum, autoimmune uveitis, allergic encephalomyelitis, acute
necrotizing hemorrhagic encephalopathy, idiopathic bilateral
progressive sensorineural hearing loss, aplastic anemia, pure red
cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's
granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome,
idiopathic sprue, lichen planus, Crohn's disease, Graves
ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis
posterior, and interstitial lung fibrosis. Thus, an autoimmune
disease can be treated by, e.g., administering to a subject having
an autoimmune disease an antibody having at least one antigen
binding region specific for human CD89 and an antigen binding
region specific for an epitope on an autoimmune cell. In one
embodiment the target epitope is an epitope on an autoantibody.
Accordingly, resting B lymphocytes having autoantibodies on their
surface can be targeted and destroyed by a multispecific antibody
bridging the B lymphocyte and an effector cell expressing CD89,
thereby inducing an effector cell function, resuling in lysis of
the B lymphocyte.
[0158] Similarly, antibodies having at least one binding
specificity for CD89 and at least one binding specificity for an
epitope on a lymphocyte producing IgE can be used to treat
allergies. The antibody for use in treating allergy in a subject
can also be a binding agent having at least one antigen binding
region specific for an epitope on an IgE antibody. Accordingly,
such a binding agent can link an effector cell expressing CD89 and
a target cell whose surface is coated with IgE, such as a basophil
and a mast cell, resulting in lysis of the target cells. Such a
treatment can also prevent binding of an antigen to the IgE
molecules and thus prevent secretion by these cells of mediators
involved in allergy, e.g., histamine. Additionally, the antibody
can bind soluble IgE and thereby prevent binding of IgE to mast
cells and basophils.
[0159] The target can also be microorganism (bacterium or virus) or
a soluble antigen (such as rheumatoid factor, or other
auto-antibodies and toxins). A microorganism is intended to include
pathogens, e.g., viruses, bacteria, fungi, protozoa. A
microorganism can also be targeted by targeting a cell infected by
a microorganism, such as a pathogen infected cell.
[0160] Accordingly, the invention provides methods for treating
infectious diseases, by, e.g., administering to a subject having an
infectious disease an efficient amount of a bispecific molecule of
the present invention having at least one antigen binding region
specific for CD89 and at least one antigen binding region specific
for an epitope on a microorganism. The term "infectious disease" is
meant to include disorders caused by one or more species of
bacteria, viruses, fungi, and protozoans, which are
disease-producing organisms collectively referred to as
"pathogens." In this invention, pathogens are exemplified, but not
limited to, Mycobacterium tuberculosis, M. leprae, Pseudomonas
aeruginosa, Shigella dysenteria, Salmonella typhi, S. paratyphi,
Staphylococcus aureus, Streptococcus hemolyticus, Hemophilus
pneumoniae, Escherichia coli serotype 0157, Chlamydia species,
Helicobacter species; HIV-1,-2, and -3, HTLV, FELV, HSV-I and -II,
hepatitis B virus, (e.g., HBV major surface antigen), non-A non-B
non-C hepatitis virus, Epstein Barr virus (EBV glycoprotein), pox
viruses, rabies viruses; Aspergillus species; Entamoeba
histolytica, Giardia species; Newcastle disease virus; Toxoplasma
gondii; and Candida albicans. Obtaining unique epitopes from these
organisms by screening proteins and by assaying peptides in vitro
are commonly known to those skilled in the art. Thus, preferred
antibodies of the invention have at least one antigen binding
region specific for an epitope on any of these microorganisms.
[0161] In a preferred embodiment, the antibody has an antigen
binding region specific for an envelope glycoprotein of an HIV
virus, e.g., gp41 of HIV. Also within the scope of the invention
are antibodies specific for gp120 or CD4. In one embodiment, the
antibody derives from the human anti-HIV-1 IgG1 mAb, DZ33.
[0162] IgA plays an important role in mucosal defense and CD89 has
been found on effector cells, e.g., monocytes and macrophages, from
mucosal areas (See e.g., Shen, L. and Collins, J. (1989) Immunology
68:491). For example, monocytes and macrophages at mucosal
surfaces, e.g., the lung, were found to express CD89 (Shen, L. and
Collins, J. (1989) Immunology 68:491). Accordingly, the invention
provides methods for eliminating microorganisms or any unwanted
cells from mucosal areas. Such methods are particularly useful in
view of the fact that mucosal sites are often entry points for
invading organisms and further in view of the fact that superoxide
is a potent microbial agent. For example, oxygen metabolites, such
as superanion have been shown to have bactericidal and
bacteriostatic effects.
[0163] An antigen binding region to a target epitope can also be a
ligand to a receptor, e.g., growth factors or differentiation
factors, which can target the binding agent to cells having a
receptor for these growth or differentiation factors. For example,
an antibody of the present invention can comprise an epidermal
growth factor (EGF), or at least a portion or modified form thereof
that is capable of interacting with an epidermal growth factor
receptor (EGF-R). The antibody can also comprise a binding portion
of heregulin. In another preferred embodiment of the invention, the
ligand is a small peptide, such as bombesin, gastrin-releasing
peptide (GRP), litorin, neuromedin B, or neuromedin C. The
sequences of the peptides can be found, e.g., in U.S. Pat. No.
5,217,955, the content of which is incorporated herein by
reference. The ligand can also be a modified form of any of these
peptides. The modification can increase binding to the receptor,
decrease binding, or not affect the binding to a receptor. The
modification of the ligand can also transform an agonist into an
antagonist, such that the ligand inhibits rather than stimulates
cell proliferation. Modification of the ligand can be an addition,
a deletion, a substitution, or a modification of at least one amino
acid.
[0164] Effector cells for targeting can be human leukocytes,
preferably macrophages. Other cells include monocytes and other
IgA-receptor bearing cells. If desired, effector cells for
targeting can be obtained from the host to be treated.
[0165] The targeted effector cells, i.e., effector cells coated
with binding agent of the invention, can be administered as a
suspension of cells in a physiologically acceptable solution. The
number of cells administered can be in the order of
10.sup.8-10.sup.9 but will vary depending on the therapeutic
purpose. In general, the amount will be sufficient to obtain
localization at the target cell and to effect target cell killing
by antibody dependent-mediated cytolysis (ADCC). Routes of
administration can also vary. In tumor therapy, for instance,
depending upon the localization of a tumor, the targeted effector
cells could be administered intravenously, or directly into tumor
sites; as for example, directly into the peritoneal cavity in the
case of ovarian carcinoma.
[0166] Bispecific and multispecific molecules of the invention can
further include a third binding specificity. In one embodiment, the
third binding specificity is an anti-enhancement factor (EF)
portion, e.g., a molecule which binds to a surface protein involved
in cytotoxic activity and thereby increases the immune response
against the target cell. The "anti-enhancement factor portion" can
be an antibody, functional antibody fragment or a ligand that binds
to a given molecule, e.g., an antigen or a receptor, and thereby
results in an enhancement of the effect of the binding determinants
for the F.sub.c receptor or target cell antigen. The
"anti-enhancement factor portion" can bind an F.sub.c receptor or a
target cell antigen. Alternatively, the anti-enhancement factor
portion can bind to an entity that is different from the entity to
which the first and second binding specificities bind. For example,
the anti-enhancement factor portion can bind a cytotoxic T-cell
(e.g. via CD2, CD3, CD8, CD28, CD4, CD40, ICAM-1 or other immune
cell that results in an increased immune response against the
target cell).
[0167] In one embodiment, the bispecific and multispecific
molecules of the invention comprise as a binding specificity at
least one antibody, or an antibody fragment thereof, including,
e.g., an Fab, Fab', F(ab').sub.2, Fv, or a single chain Fv. The
antibody may also be a light chain or heavy chain dimer, or any
minimal fragment thereof such as a Fv or a single chain construct
as described in Ladner et al. U.S. Pat. No. 4,946,778, issued Aug.
7, 1990, the contents of which is expressly incorporated by
reference.
[0168] While human monoclonal antibodies are preferred, other
antibodies which can be employed in the bispecific or multispecific
molecules of the invention are murine, chimeric and humanized
monoclonal antibodies.
[0169] Chimeric mouse-human monoclonal antibodies (i.e., chimeric
antibodies) can be produced by recombinant DNA techniques known in
the art. For example, a gene encoding the Fc constant region of a
murine (or other species) monoclonal antibody molecule is digested
with restriction enzymes to remove the region encoding the murine
Fc, and the equivalent portion of a gene encoding a human Fc
constant region is substituted. (see Robinson et al., International
Patent Publication PCT/US86/02269; Akira, et al., European Patent
Application 184,187; Taniguchi, M., European Patent Application
171,496; Morrison et al., European Patent Application 173,494;
Neuberger et al., International Application WO 86/01533; Cabilly et
al. U.S. Pat. No. 4,816,567; Cabilly et al., European Patent
Application 125,023; Better et al. (1988 Science 240:1041-1043);
Liu et al. (1987) PNAS 84:3439-3443; Liu et al., 1987, J. Immunol.
139:3521-3526; Sun et al. (1987) PNAS 84:214-218; Nishimura et al.,
1987, Canc. Res. 47:999-1005; Wood et al. (1985) Nature
314:446-449; and Shaw et al., 1988, J. Natl Cancer Inst.
80:1553-1559).
[0170] The chimeric antibody can be further humanized by replacing
sequences of the Fv variable region which are not directly involved
in antigen binding with equivalent sequences from human Fv variable
regions. General reviews of humanized chimeric antibodies are
provided by Morrison, S. L., 1985, Science 229:1202-1207 and by Oi
et al., 1986, BioTechniques 4:214. Those methods include isolating,
manipulating, and expressing the nucleic acid sequences that encode
all or part of immunoglobulin Fv variable regions from at least one
of a heavy or light chain. Sources of such nucleic acid are well
known to those skilled in the art and, for example, may be obtained
from 7E3, an anti-GPII.sub.bIII.sub.a antibody producing hybridoma.
The recombinant DNA encoding the chimeric antibody, or fragment
thereof, can then be cloned into an appropriate expression vector.
Suitable humanized antibodies can alternatively be produced by CDR
substitution U.S. Pat. No. 5,225,539; Jones et al. 1986 Nature
321:552-525; Verhoeyan et al. 1988 Science 239:1534; and Beidler et
al. 1988 J. Immunol. 141:4053-4060.
[0171] All of the CDRs of a particular human antibody may be
replaced with at least a portion of a non-human CDR or only some of
the CDRs may be replaced with non-human CDRs. It is only necessary
to replace the number of CDRs required for binding of the humanized
antibody to the Fc receptor.
[0172] An antibody can be humanized by any method, which is capable
of replacing at least a portion of a CDR of a human antibody with a
CDR derived from a non-human antibody. Winter describes a method
which may be used to prepare the humanized antibodies of the
present invention (UK Patent Application GB 2188638A, filed on Mar.
26, 1987), the contents of which is expressly incorporated by
reference. The human CDRs may be replaced with non-human CDRs using
oligonucleotide site-directed mutagenesis as described in
International Application WO 94/10332 entitled, Humanized
Antibodies to Fc Receptors for Immunoglobulin G on Human
Mononuclear Phagocytes.
[0173] Also within the scope of the invention are chimeric and
humanized antibodies in which specific amino acids have been
substituted, deleted or added. In particular, preferred humanized
antibodies have amino acid substitutions in the framework region,
such as to improve binding to the antigen. For example, in a
humanized antibody having mouse CDRs, amino acids located in the
human framework region can be replaced with the amino acids located
at the corresponding positions in the mouse antibody. Such
substitutions are known to improve binding of humanized antibodies
to the antigen in some instances. Antibodies in which amino acids
have been added, deleted, or substituted are referred to herein as
modified antibodies or altered antibodies.
[0174] The term modified antibody is also intended to include
antibodies, such as monoclonal antibodies, chimeric antibodies, and
humanized antibodies which have been modified by, e.g., deleting,
adding, or substituting portions of the antibody. For example, an
antibody can be modified by deleting the constant region and
replacing it with a constant region meant to increase half-life,
e.g., serum half-life, stability or affinity of the antibody. Any
modification is within the scope of the invention so long as the
bispecific and multispecific molecule has at least one antigen
binding region specific for CD89 and triggers at least one effector
function.
[0175] Bispecific and multispecific molecules of the present
invention can be made using chemical techniques (see e.g., D. M.
Kranz et al. (1981) Proc. Natl. Acad. Sci. USA 78:5807), "polydoma"
techniques (See U.S. Pat. No. 4,474,893, to Reading), or
recombinant DNA techniques.
[0176] In particular, bispecific and multispecific molecules of the
present invention can be prepared by conjugating the constituent
binding specificities, e.g., the anti-target cell and anti-CD89
binding specificities, using methods known in the art and described
in the examples provided herein. For example, each binding
specificity of the bispecific and multispecific molecule can be
generated separately and then conjugated to one another. When the
binding specificities are proteins or peptides, a variety of
coupling or cross-linking agents can be used for covalent
conjugation. Examples of cross-linking agents include protein A,
carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA),
5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide
(oPDM), N-succinimidyl-3-(2-pyridyldithio)propiona- te (SPDP), and
sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohaxane-1-carboxylate
(sulfo-SMCC) (see e.g., Karpovsky et al. (1984) J. Exp. Med.
160:1686; Liu, Mass. et al. (1985) Proc. Natl. Acad. Sci. USA
82:8648). Other methods include those described by Paulus (Behring
Ins. Mitt. (1985) No. 78, 118-132); Brennan et al. (Science (1985)
229:81-83), and Glennie et al. (J. Immunol. (1987) 139: 2367-2375).
Preferred conjugating agents are SATA and sulfo-SMCC, both
available from Pierce Chemical Co. (Rockford, Ill.).
[0177] When the binding specificities are antibodies (e.g., two
humanized antibodies), they can be conjugated via sulfhydryl
bonding of the C-terminus hinge regions of the two heavy chains. In
a particularly preferred embodiment, the hinge region is modified
to contain an odd number of sulfhydryl residues, preferably one,
prior to conjugation.
[0178] Alternatively, both binding specificities can be encoded in
the same vector and expressed and assembled in the same host cell.
This method is particularly useful where the bispecific and
multispecific molecule is a mAb.times.mAb, mAb.times.Fab,
Fab.times.F(ab').sub.2 or ligand.times.Fab fusion protein. A
bispecific and multispecific molecule of the invention, e.g., a
bispecific molecule can be a single chain molecule, such as a
single chain bispecific antibody, a single chain bispecific
molecule comprising one single chain antibody and a binding
determinant, or a single chain bispecific molecule comprising two
binding determinants. Bispecific and multispecific molecules can
also be single chain molecules or may comprise at least two single
chain molecules. Methods for preparing bi- and multspecific
molecules are described for example in U.S. Pat. No. 5,260,203;
U.S. Pat. No. 5,455,030; U.S. Pat. No. 4,881,175; U.S. Pat. No.
5,132,405; U.S. Pat. No. 5,091,513; U.S. Pat. No. 5,476,786; U.S.
Pat. No. 5,013,653; U.S. Pat. No. 5,258,498; and U.S. Pat. No.
5,482,858.
[0179] Binding of the bispecific and multispecific molecules to
their specific targets can be confirmed by enzyme-linked
immunosorbent assay (ELISA), a radioimmunoassay (RIA), FACS
analysis, a bioassay (e.g., growth inhibition), or a Western Blot
Assay. Each of these assays generally detects the presence of
protein-antibody complexes of particular interest by employing a
labeled reagent (e.g., an antibody) specific for the complex of
interest. For example, the FcR-antibody complexes can be detected
using e.g., an enzyme-linked antibody or antibody fragment which
recognizes and specifically binds to the antibody-FcR complexes.
Alternatively, the complexes can be detected using any of a variety
of other immunoassays. For example, the antibody can be
radioactively labeled and used in a radioimmunoassay (RIA) (see,
for example, Weintraub, B., Principles of Radioimmunoassays,
Seventh Training Course on Radioligand Assay Techniques, The
Endocrine Society, March, 1986, which is incorporated by reference
herein). The radioactive isotope can be detected by such means as
the use of a .gamma. counter or a scintillation counter or by
autoradiography.
[0180] IV. Binding Assays
[0181] Several assays can be performed to show that an antibody, or
antigen-binding portion thereof, of the present invention
specifically bind to CD89, such as human CD89. For example, binding
assays comparing binding of the antibody and that of IgA to a
variety of cells, some of which are bound by IgA (e.g., monocytes
and macrophages) and some of which are not bound by IgA (e.g.,
K-562 cells), can be performed. The antibody of the invention
should bind substantially to the same set of cells as IgA.
Competition binding experiments using the antibody and IgA will
indicate whether both agents recognize the same epitope. Binding
experiments can be flow cytometry experiments, indirect
immunofluorescence assays, or ELISAs, among others. Further, IgA
and the antibody should immunoprecipitate a protein having similar
molecular weight form the same cell. In addition, preclearing with
IgA of a cell lysate having CD89 should result in
immunoprecipitation of less protein with the antibody than in the
absence of preclearing. Similarly, preclearing with the antibody of
the cell lysate should result in immunoprecipitation of less
protein with IgA than in the absence of preclearing. Other tests
for showing that the same antigen is recognized by an antibody, or
antigen-binding portion thereof, of the invention and IgA are known
in the art. In addition, since CD89 has been cloned, e.g., human
CD89, it is possible to use recombinantly produced CD89, or
portions thereof, or cells transfected to express CD89 to show
binding of an antibody to CD89.
[0182] In one embodiment, antibodies of the invention stimulate
phagocytosis of target cells by effector cells when the antibody
links the target cell to the effector cell. For example, preferred
bispecific antibodies of the invention having at least one antigen
binding region specific for CD89 and one antigen binding region to
an epitope on a target cell can induce phagocytosis of the target
cell. In fact, it has been shown that a heteroantibody of My 43 (a
mouse anti-CD89 antibody) linked to anti-erythrocyte F(ab)'.sub.2
mediates erythrocyte phagocytosis by monocytes. Phagocytosis assays
can be performed as follows. Packed target cells, e.g., ox
erythrocytes (OE) (10 .mu.l) are mixed for 16 hours at 10.degree.
C. with 20 .mu.l of the F(ab').sub.2-Ig conjugates at
concentrations previously determined to give maximal rosette
formation. Heteroantibody-coated OE are washed, adjusted to
4.times.10.sup.7 cells/ml, and are mixed with an equal volume of
myeloid cells at 2.times.10.sup.6 cells/ml. This mixture is
incubated for 10 min at 37.degree. C., and the cells are pelleted
and incubated for a further 20 min, after which time noningested OE
are lysed at 4.degree. C. with buffered ammonium chloride.
Phagocytosis can be assessed by microscopic examination of Wright's
Giemsa (Sigma) stained cytospin preparations. At least 200 cells
are counted in duplicate slides. Phagocytosis can be quantified as
the percentage of cells containing one or more ingested
erythrocyte(s).
[0183] A preferred antibody triggers an oxidative burst, i.e.,
production of superoxide anion in an effector cell upon binding to
CD89 on the effector cell. For example, it was shown that My 43 (a
mouse anti-CD89 antibody) triggers production of superoxide anion
by interferon-.gamma. treated U937 cells.
[0184] A superoxide assay can be performed on a solid phase or in
solution. A solid phase superoxide assay can be performed as
follows. Flat bottom 6-well PVC tissue culture places (Falcon
Plastics Baxter Corporation, Bedford, Mass.) can be treated for 30
minutes at room temperature with 1 ml per well of poly-L-lysine
(Sigma, St. Louis, Mo.) at 100 .mu.g/ml in PBS. After aspirating
dry, glutaradehyde (2%, Sigma) can be added and incubated at room
temperature for 15 min. After four washes with PBS, 1 ml of PBS
containing the desired amount of Ig can be added, and incubated at
ambient temperature for 2 hours. The wells can then be washed with
PBS, filled with 100 mM glycine/0.1% BSA in PBS and incubated at
4.degree. C. for 18 hours. They can then be washed twice with PBS
and once in Krebs Ringer Hepes buffered salt solution (KRH) and
3.times.10+6 cells/well were added in KRH containing 1 mM KCN and 1
mg/mnl horse heart ferricytochrome c (Sigma). The cells can be spun
down onto the plates for 5 minutes at 100 x g and incubated at
37.degree. C. PMA (Sigma) as added to positive controls to final
concentrations indicated. After 30 min, the contents can be
removed, spun down, and the supernatant read at 550 nm in a
Dynatech spectrophotometer (Dynatech Labs, Chantilly, Va.).
[0185] Suspension superoxide assay can be performed as follows.
Cells can be incubated with mAb at 4.degree. C. for 45 minutes,
then washed in KRH, resuspended in KRH containing 1 mM KCN and 1
mg/ml horse heart ferricytochrome c (Sigma), and incubation at
37.degree. C. initiated. PMA (Sigma) can be added to positive
controls at the concentrations indicated. After 30 minutes, the
samples can be removed, spun down, and the supernatant read at 550
nm in a Dynatech spectrophotometer (Dynatech Labs).
[0186] V. Antibody Conjugates/Immunotoxins
[0187] In another aspect, the present invention features a human
anti-CD89 monoclonal antibody, or a fragment thereof, conjugated to
a therapeutic moiety, such as a cytotoxin, a drug or a
radioisotope. When conjugated to a cytotoxin, these antibody
conjugates are referred to as "immunotoxins." A cytotoxin or
cytotoxic agent includes any agent that is detrimental to (e.g.,
kills) cells. Examples include taxol, cytochalasin B, gramicidin D,
ethidium bromide, emetine, mitomycin, etoposide, tenoposide,
vincristine, vinblastine, colchicin, doxorubicin, daunorubicin,
dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin
D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine,
lidocaine, propranolol, and puromycin and analogs or homologs
thereof. Therapeutic agents include, but are not limited to,
antimetabolites (e.g., methotrexate, 6-mercaptopurine,
6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating
agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan,
carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan,
dibromomannitol, streptozotocin, mitomycin C, and
cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines
(e.g., daunorubicin (formerly daunomycin) and doxorubicin),
antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin,
mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g.,
vincristine and vinblastine). An antibody of the present invention
can be conjugated to a radioisotope, e.g., radioactive iodine, to
generate cytotoxic radiopharmaceuticals for treating a CD89-related
disorder, such as a cancer.
[0188] The antibody conjugates of the invention can be used to
modify a given biological response, and the drug moiety is not to
be construed as limited to classical chemical therapeutic agents.
For example, the drug moiety may be a protein or polypeptide
possessing a desired biological activity. Such proteins may
include, for example, an enzymatically active toxin, or active
fragment thereof, such as abrin, ricin A, pseudomonas exotoxin, or
diphtheria toxin; a protein such as tumor necrosis factor or
interferon-.gamma.; or, biological response modifiers such as, for
example, lymphokines, interleukin-1 ("IL-1"), interleukin-2
("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony
stimulating factor ("GM-CSF"), granulocyte colony stimulating
factor ("G-CSF"), or other growth factors.
[0189] Techniques for conjugating such therapeutic moiety to
antibodies are well known, see, e.g., Arnon et al., "Monoclonal
Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in
Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.),
pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies
For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson
et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe,
"Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A
Review", in Monoclonal Antibodies '84: Biological And Clinical
Applications, Pinchera et al. (eds.), pp. 475-506 (1985);
"Analysis, Results, And Future Prospective Of The Therapeutic Use
Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal
Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.),
pp. 303-16 (Academic Press 1985), and Thorpe et al., "The
Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates",
Immunol. Rev., 62:119-58 (1982).
[0190] VI. Pharmaceutical Compositions
[0191] In another aspect, the present invention provides a
composition, e.g., a pharmaceutical composition, containing one or
a combination of human monoclonal antibodies, or antigen-binding
portion(s) thereof, of the present invention, formulated together
with a pharmaceutically acceptable carrier. In a preferred
embodiment, the compositions include a combination of multiple
(e.g., two or more) isolated human antibodies or antigen-binding
portions thereof of the invention. Preferably, each of the
antibodies or antigen-binding portions thereof of the composition
binds to a distinct, pre-selected epitope of CD89.
[0192] In one embodiment, the composition comprises one or a
combination of bispecific or multispecific molecules of the
invention (e.g., which contains at least one binding specificity
for a target cell and at least one binding specificity for
CD89).
[0193] Pharmaceutical compositions of the invention also can be
administered in combination therapy, i.e., combined with other
agents. For example, the combination therapy can include a
composition of the present invention with at least one anti-tumor
agent or other conventional therapy.
[0194] As used herein, "pharmaceutically acceptable carrier"
includes any and all solvents, dispersion media, coatings,
antibacterial and antifungal agents, isotonic and absorption
delaying agents, and the like that are physiologically compatible.
Preferably, the carrier is suitable for intravenous, intramuscular,
subcutaneous, parenteral, spinal or epidermal administration (e.g.,
by injection or infusion). Depending on the route of
administration, the active compound, i.e., antibody, bispecific and
multispecific molecule, may be coated in a material to protect the
compound from the action of acids and other natural conditions that
may inactivate the compound.
[0195] A "pharmaceutically acceptable salt" refers to a salt that
retains the desired biological activity of the parent compound and
does not impart any undesired toxicological effects (see e.g.,
Berge, S. M., et al. (1977) J. Pharm. Sci. 66:1-19). Examples of
such salts include acid addition salts and base addition salts.
Acid addition salts include those derived from nontoxic inorganic
acids, such as hydrochloric, nitric, phosphoric, sulfuric,
hydrobromic, hydroiodic, phosphorous and the like, as well as from
nontoxic organic acids such as aliphatic mono- and dicarboxylic
acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids,
aromatic acids, aliphatic and aromatic sulfonic acids and the like.
Base addition salts include those derived from alkaline earth
metals, such as sodium, potassium, magnesiun, calcium and the like,
as well as from nontoxic organic amines, such as
N,N'-dibenzylethylenediamin- e, N-methylglucamine, chloroprocaine,
choline, diethanolamine, ethylenediamine, procaine and the
like.
[0196] A composition of the present invention can be administered
by a variety of methods known in the art. As will be appreciated by
the skilled artisan, the route and/or mode of administration will
vary depending upon the desired results. The active compounds can
be prepared with carriers that will protect the compound against
rapid release, such as a controlled release formulation, including
implants, transdermal patches, and microencapsulated delivery
systems. Biodegradable, biocompatible polymers can be used, such as
ethylene vinyl acetate, polyanhydrides, polyglycolic acid,
collagen, polyorthoesters, and polylactic acid. Many methods for
the preparation of such formulations are patented or generally
known to those skilled in the art. See, e.g., Sustained and
Controlled Release Drug Delivery Systems, J. R. Robinson, ed.,
Marcel Dekker, Inc., New York, 1978.
[0197] To administer a compound of the invention by certain routes
of administration, it may be necessary to coat the compound with,
or co-administer the compound with, a material to prevent its
inactivation. For example, the compound may be administered to a
subject in an appropriate carrier, for example, liposomes, or a
diluent. Pharmaceutically acceptable diluents include saline and
aqueous buffer solutions. Liposomes include water-in-oil-in-water
CGF emulsions as well as conventional liposomes (Strejan et al.
(1984) J. Neuroimmunol. 7:27).
[0198] Pharmaceutically acceptable carriers include sterile aqueous
solutions or dispersions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or dispersion. The use
of such media and agents for pharmaceutically active substances is
known in the art. Except insofar as any conventional media or agent
is incompatible with the active compound, use thereof in the
pharmaceutical compositions of the invention is contemplated.
Supplementary active compounds can also be incorporated into the
compositions.
[0199] Therapeutic compositions typically must be sterile and
stable under the conditions of manufacture and storage. The
composition can be formulated as a solution, microemulsion,
liposome, or other ordered structure suitable to high drug
concentration. The carrier can be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol, and the
like), and suitable mixtures thereof. The proper fluidity can be
maintained, for example, by the use of a coating such as lecithin,
by the maintenance of the required particle size in the case of
dispersion and by the use of surfactants. In many cases, it will be
preferable to include isotonic agents, for example, sugars,
polyalcohols such as mannitol, sorbitol, or sodium chloride in the
composition. Prolonged absorption of the injectable compositions
can be brought about by including in the composition an agent that
delays absorption, for example, monostearate salts and gelatin.
[0200] Sterile injectable solutions can be prepared by
incorporating the active compound in the required amount in an
appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by sterilization
microfiltration. Generally, dispersions are prepared by
incorporating the active compound into a sterile vehicle that
contains a basic dispersion medium and the required other
ingredients from those enumerated above. In the case of sterile
powders for the preparation of sterile injectable solutions, the
preferred methods of preparation are vacuum drying and
freeze-drying (lyophilization) that yield a powder of the active
ingredient plus any additional desired ingredient from a previously
sterile-filtered solution thereof.
[0201] Dosage regimens are adjusted to provide the optimum desired
response (e.g., a therapeutic response). For example, a single
bolus may be administered, several divided doses may be
administered over time or the dose may be proportionally reduced or
increased as indicated by the exigencies of the therapeutic
situation. It is especially advantageous to formulate parenteral
compositions in dosage unit form for ease of administration and
uniformity of dosage. Dosage unit form as used herein refers to
physically discrete units suited as unitary dosages for the
subjects to be treated; each unit contains a predetermined quantity
of active compound calculated to produce the desired therapeutic
effect in association with the required pharmaceutical carrier. The
specification for the dosage unit forms of the invention are
dictated by and directly dependent on (a) the unique
characteristics of the active compound and the particular
therapeutic effect to be achieved, and (b) the limitations inherent
in the art of compounding such an active compound for the treatment
of sensitivity in individuals.
[0202] Examples of pharmaceutically-acceptable antioxidants
include: (1) water soluble antioxidants, such as ascorbic acid,
cysteine hydrochloride, sodium bisulfate, sodium metabisulfite,
sodium sulfite and the like; (2) oil-soluble antioxidants, such as
ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol,
and the like; and (3) metal chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,
phosphoric acid, and the like.
[0203] For the therapeutic compositions, formulations of the
present invention include those suitable for oral, nasal, topical
(including buccal and sublingual), rectal, vaginal and/or
parenteral administration. The formulations may conveniently be
presented in unit dosage form and may be prepared by any methods
known in the art of pharmacy. The amount of active ingredient which
can be combined with a carrier material to produce a single dosage
form will vary depending upon the subject being treated, and the
particular mode of administration. The amount of active ingredient
which can be combined with a carrier material to produce a single
dosage form will generally be that amount of the composition which
produces a therapeutic effect. Generally, out of one hundred
percent, this amount will range from about 0.01 percent to about
ninety-nine percent of active ingredient, preferably from about 0.1
percent to about 70 percent, most preferably from about 1 percent
to about 30 percent.
[0204] Formulations of the present invention which are suitable for
vaginal administration also include pessaries, tampons, creams,
gels, pastes, foams or spray formulations containing such carriers
as are known in the art to be appropriate. Dosage forms for the
topical or transdermal administration of compositions of this
invention include powders, sprays, ointments, pastes, creams,
lotions, gels, solutions, patches and inhalants. The active
compound may be mixed under sterile conditions with a
pharmaceutically acceptable carrier, and with any preservatives,
buffers, or propellants which may be required.
[0205] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular,
subarachnoid, intraspinal, epidural and intrasternal injection and
infusion.
[0206] Examples of suitable aqueous and nonaqueous carriers which
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained,
for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0207] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of presence of microorganisms may be ensured
both by sterilization procedures, supra, and by the inclusion of
various antibacterial and antifungal agents, for example, paraben,
chlorobutanol, phenol sorbic acid, and the like. It may also be
desirable to include isotonic agents, such as sugars, sodium
chloride, and the like into the compositions. In addition,
prolonged absorption of the injectable pharmaceutical form may be
brought about by the inclusion of agents which delay absorption
such as aluminum monostearate and gelatin.
[0208] When the compounds of the present invention are administered
as pharmaceuticals, to humans and animals, they can be given alone
or as a pharmaceutical composition containing, for example, 0.01 to
99.5% (more preferably, 0.1 to 90%) of active ingredient in
combination with a pharmaceutically acceptable carrier.
[0209] Regardless of the route of administration selected, the
compounds of the present invention, which may be used in a suitable
hydrated form, and/or the pharmaceutical compositions of the
present invention, are formulated into pharmaceutically acceptable
dosage forms by conventional methods known to those of skill in the
art.
[0210] Actual dosage levels of the active ingredients in the
pharmaceutical compositions of the present invention may be varied
so as to obtain an amount of the active ingredient which is
effective to achieve the desired therapeutic response for a
particular patient, composition, and mode of administration,
without being toxic to the patient. The selected dosage level will
depend upon a variety of pharmacokinetic factors including the
activity of the particular compositions of the present invention
employed, or the ester, salt or amide thereof, the route of
administration, the time of administration, the rate of excretion
of the particular compound being employed, the duration of the
treatment, other drugs, compounds and/or materials used in
combination with the particular compositions employed, the age,
sex, weight, condition, general health and prior medical history of
the patient being treated, and like factors well known in the
medical arts.
[0211] A physician or veterinarian having ordinary skill in the art
can readily determine and prescribe the effective amount of the
pharmaceutical composition required. For example, the physician or
veterinarian could start doses of the compounds of the invention
employed in the pharmaceutical composition at levels lower than
that required in order to achieve the desired therapeutic effect
and gradually increase the dosage until the desired effect is
achieved. In general, a suitable daily dose of a compositions of
the invention will be that amount of the compound which is the
lowest dose effective to produce a therapeutic effect. Such an
effective dose will generally depend upon the factors described
above. It is preferred that administration be intravenous,
intramuscular, intraperitoneal, or subcutaneous, preferably
administered proximal to the site of the target. If desired, the
effective daily dose of a therapeutic compositions may be
administered as two, three, four, five, six or more sub-doses
administered separately at appropriate intervals throughout the
day, optionally, in unit dosage forms. While it is possible for a
compound of the present invention to be administered alone, it is
preferable to administer the compound as a pharmaceutical
formulation (composition).
[0212] Therapeutic compositions can be administered with medical
devices known in the art. For example, in a preferred embodiment, a
therapeutic composition of the invention can be administered with a
needleless hypodermic injection device, such as the devices
disclosed in U.S. Pat. Nos. 5,399,163; 5,383,851; 5,312,335;
5,064,413; 4,941,880; 4,790,824; or 4,596,556. Examples of
well-known implants and modules useful in the present invention
include: U.S. Pat. No. 4,487,603, which discloses an implantable
micro-infusion pump for dispensing medication at a controlled rate;
U.S. Pat. No. 4,486,194, which discloses a therapeutic device for
administering medicants through the skin; U.S. Pat. No. 4,447,233,
which discloses a medication infusion pump for delivering
medication at a precise infusion rate; U.S. Pat. No. 4,447,224,
which discloses a variable flow implantable infusion apparatus for
continuous drug delivery; U.S. Pat. No. 4,439,196, which discloses
an osmotic drug delivery system having multi-chamber compartments;
and U.S. Pat. No. 4,475,196, which discloses an osmotic drug
delivery system. These patents are incorporated herein by
reference. Many other such implants, delivery systems, and modules
are known to those skilled in the art.
[0213] In certain embodiments, the human monoclonal antibodies of
the invention can be formulated to ensure proper distribution in
vivo. For example, the blood-brain barrier (BBB) excludes many
highly hydrophilic compounds. To ensure that the therapeutic
compounds of the invention cross the BBB (if desired), they can be
formulated, for example, in liposomes. For methods of manufacturing
liposomes, see, e.g., U.S. Pat. Nos. 4,522,811; 5,374,548; and
5,399,331. The liposomes may comprise one or more moieties which
are selectively transported into specific cells or organs, thus
enhance targeted drug delivery (see, e.g., V. V. Ranade (1989) J.
Clin. Pharmacol. 29:685). Exemplary targeting moieties include
folate or biotin (see, e.g., U.S. Pat. No. 5,416,016 to Low et
al.); mannosides (Umezawa et al., (1988) Biochem. Biophys. Res.
Commun. 153:1038); antibodies (P. G. Bloeman et al. (1995) FEBS
Lett. 357:140; M. Owais et al. (1995) Antimicrob. Agents Chemother.
39:180); surfactant protein A receptor (Briscoe et al. (1995) Am.
J. Physiol. 1233:134), different species of which may comprise the
formulations of the inventions, as well as components of the
invented molecules; p120 (Schreier et al. (1994) J. Biol. Chem.
269:9090); see also K. Keinanen; M. L. Laukkanen (1994) FEBS Lett.
346:123; J. J. Killion; I. J. Fidler (1994) Immunomethods 4:273. In
one embodiment of the invention, the therapeutic compounds of the
invention are formulated in liposomes; in a more preferred
embodiment, the liposomes include a targeting moiety. In a most
preferred embodiment, the therapeutic compounds in the liposomes
are delivered by bolus injection to a site proximal to the tumor or
infection. The composition must be fluid to the extent that easy
syringability exists. It must be stable under the conditions of
manufacture and storage and must be preserved against the
contaminating action of microorganisms such as bacteria and
fungi.
[0214] A "therapeutically effective dosage" preferably inhibits
tumor growth by at least about 20%, more preferably by at least
about 40%, even more preferably by at least about 60%, and still
more preferably by at least about 80% relative to untreated
subjects. The ability of a compound to inhibit cancer can be
evaluated in an animal model system predictive of efficacy in human
tumors. Alternatively, this property of a composition can be
evaluated by examining the ability of the compound to inhibit, such
inhibition in vitro by assays known to the skilled practitioner. A
therapeutically effective amount of a therapeutic compound can
decrease tumor size, or otherwise ameliorate symptoms in a subject.
One of ordinary skill in the art would be able to determine such
amounts based on such factors as the subject's size, the severity
of the subject's symptoms, and the particular composition or route
of administration selected.
[0215] The composition must be sterile and fluid to the extent that
the composition is deliverable by syringe. In addition to water,
the carrier can be an isotonic buffered saline solution, ethanol,
polyol (for example, glycerol, propylene glycol, and liquid
polyetheylene glycol, and the like), and suitable mixtures thereof.
Proper fluidity can be maintained, for example, by use of coating
such as lecithin, by maintenance of required particle size in the
case of dispersion and by use of surfactants. In many cases, it is
preferable to include isotonic agents, for example, sugars,
polyalcohols such as manitol or sorbitol, and sodium chloride in
the composition. Long-term absorption of the injectable
compositions can be brought about by including in the composition
an agent which delays absorption, for example, aluminum
monostearate or gelatin.
[0216] When the active compound is suitably protected, as described
above, the compound may be orally administered, for example, with
an inert diluent or an assimilable edible carrier.
[0217] VII. Uses and Methods of the Invention
[0218] The compositions (e.g., human monoclonal antibodies to CD89
and derivatives/conjugates thereof) of the present invention have
in vitro and in vivo diagnostic and therapeutic utilities. For
example, these molecules can be administered to cells in culture,
e.g. in vitro or ex vivo, or in a subject, e.g., in vivo, to treat,
prevent or diagnose a variety of disorders. As used herein, the
term "subject" is intended to include human and non-human animals.
Preferred human animals include a human patient having disorder
characterized by expression, typically aberrant expression (e.g.,
overexpression) of CD89.
[0219] For example, the compositions can be used in vitro or in
vivo to diagnose diseases mediated by CD89. The antibodies of the
invention can be used to detect levels of CD89, or levels of cells
which contain CD89 on their membrane surface, which levels can then
be linked to certain disease symptoms. Alternatively, the
antibodies can be used to inhibit or block CD89 function which, in
turn, can be linked to the prevention or amelioration of certain
disease symptoms, thereby implicating CD89 as a mediator of the
disease. This can be achieved by contacting a sample and a control
sample with the anti-CD89 antibody under conditions that allow for
the formation of a complex between the antibody and CD89. Any
complexes formed between the antibody and CD89 are detected and
compared in the sample and the control.
[0220] In another embodiment, human antibodies, or binding portions
thereof, of the present invention can be used to modulate CD89
levels on effector cells, such as by capping and eliminating
receptors on the cell surface. Mixtures of anti-Fc receptor
antibodies can also be used for this purpose.
[0221] Further within the scope of the invention are methods for
treating a disorder, such as an autoimmune disorder, a cancer, or a
pathogenic infection with the bispecific and multispecific human
antibodies described above. Such antibodies include at least one
binding specificity for CD89 and at least one binding specificity
for an antigen binding region to a target antigen. In another
embodiment, the antibody includes a third binding specificity to a
binding specificity for an antigen binding region to a different
epitope of the same target antigen and/or receptor. Methods for
eliminating unwanted cells, i.e., target cells, or antigen in a
subject includes treating the subject with the bispecific or
multispecific antibodies of the invention. In one embodiment, such
methods include obtaining an aliquot of a sample of blood or blood
cells from a subject, treating the blood or blood cells ex vivo
with a therapeutically effective dose of a bispecific or
multispecific antibody of the invention in a pharmaceutically
acceptable carrier, and returning the treated blood or blood cells
to the subject. Preferably, the cells of the sample of blood are
isolated and expanded in culture and, more preferably, the cells of
the sample of blood are treated with agents that enhance the number
or activity of CD89. Such agents include cytokines, lymphokines, or
growth factors, e.g., G-CSF, GM-CSF, IFN-.gamma., TNF, and
interleukins such as IL-2, IL-10, and IL-12.
[0222] In another embodiment, the invention provides methods for
immunizing a subject against a cancer antigen, an antigen found on
a pathogen or a cell infected by a pathogen. Such methods include
administering in a pharmaceutically acceptable carrier a
composition comprising a bispecific or multispecific antibody
having a binding specificity for CD89 and a binding specificity for
an epitope of a pathogenic infectious organism, or of an antigen of
an infected cell, or of a cancer cell to a subject. Alternatively,
the composition can comprise an anti-CD89 antibody linked to one or
more antigens of a pathogenic infectious organism, or of an antigen
of infected cells, or of a cancer cell.
[0223] In another embodiment, human antibodies of the present
invention which block or inhibit IgA binding to CD89 are used in
the treatment of diseases characterized by abnormal endogenous IgA,
such as diseases characterized by circulating IgA-containing
complexes and/or precipitation of IgA-immune complexes, e.g.,
chronic hepatitis, Henoch-Schonlein purpura (HSP), IgA nephropathy
(Berger's disease), or IgA-glomerulonephritis. Human anti-CD89
antibodies of the invention can be administered to patients
suffering from such disorders to inhibit or downregulate the
binding of endogenous IgA to CD89. For example, although not
intending to be limited by mechanism, administration of an
anti-CD89 antibody of the invention can result in blocking of CD89
such that the endogenous abnormal IgA is unable to engage the
receptors and thus unable to trigger undesirable effector
functions.
[0224] In another embodiment, the human monoclonal antibodies of
the present invention have the advantage of not inducing, or
inducing only to a minimal extent, complement-mediated lysis of
cells and, therefore, have fewer side effects in triggering
complement-activated afflictions, such as, for example, acne.
[0225] Suitable methods of administering the compositions (e.g.,
human antibodies, multispecific and bispecific molecules) of the
invention are known in the art of antibody-based therapies.
Suitable dosages of the molecules used will depend on the age and
weight of the subject and the particular drug used. The molecules
can be coupled to radionuclides, such as 131I, 90Y, 105Rh, etc., as
described in Goldenberg, D. M. et al. (1981) Cancer Res. 41:
4354-4360, and in EP 0365 997. The compositions (e.g, human
antibodies, multispecific and bispecific molecules) of the
invention can also be coupled to anti-infectious agents.
[0226] Human anti-CD89 antibodies, or antigen binding fragments
thereof, also can be co-administered with another therapeutic
agent, e.g., a cytokine or a chemotherapeutic agent, or can be
co-administered with other known therapies, e.g., an anti-cancer
therapy, e.g., radiation. Such therapeutic agents include, among
others, cytokines such as G-CSF, GM-CSF, IL-2, IFN-.gamma. and
IFN-.alpha., anti-neoplastic agents such as doxorubicin
(adriamycin), cisplatin bleomycin sulfate, carmustine,
chlorambucil, and cyclophosphamide hydroxyurea which, by
themselves, are only effective at levels which are toxic or
subtoxic to a patient. Cisplatin is intravenously administered as a
100 mg/m.sup.2 dose once every four weeks and adriamycin is
intravenously administered as a 60-75 mg/m.sup.2 dose once every 21
days. Co-administration of the human anti-CD89 antibodies, or
antigen binding fragments thereof, of the present invention with
chemotherapeutic agents provides two anti-cancer agents which
operate via different mechanisms which yield a cytotoxic effect to
human tumor cells. Such co-administration can solve problems due to
development of resistance to drugs or a change in the antigenicity
of the tumor cells which would render them unreactive with the
antibody.
[0227] The compositions (e.g, human antibodies, multispecific and
bispecific molecules) of the invention which have complement
binding sites, such as portions from IgG1, -2, or -3 or IgM which
bind complement, can also be used in the presence of complement. In
one embodiment, ex vivo treatment of a population of cells
comprising target cells with a binding agent of the invention and
appropriate effector cells can be supplemented by the addition of
complement or serum containing complement. Phagocytosis of target
cells coated with a binding agent of the invention can be improved
by binding of complement proteins. In another embodiment target
cells coated with the compositions (e.g., human antibodies,
multispecific and bispecific molecules) of the invention can also
be lysed by complement. In yet another embodiment, the compositions
of the invention do not activate complement.
[0228] The compositions (e.g., human antibodies, multispecific and
bispecific molecules) of the invention can also be administered
together with complement. Accordingly, within the scope of the
invention are compositions comprising human antibodies,
multispecific or bispecific molecules and serum or complement.
These compositions are advantageous in that the complement is
located in close proximity to the human antibodies, multispecific
or bispecific molecules. Alternatively, the human antibodies,
multispecific or bispecific molecules of the invention and the
complement or serum can be administered separately.
[0229] Also within the scope of the invention are kits comprising
the compositions (e.g., human antibodies, multispecific and
bispecific molecules) of the invention and instructions for use.
The kit can further contain a least one additional reagent, such as
complement, or one or more additional human antibodies of the
invention (e.g, a human antibody having a complementary activity
which binds to an epitope of a CD89 antigen which is distinct from
the first human antibody).
[0230] The compositions (e.g., human antibodies, multispecific, and
bispecific molecules) of the invention can also be used to target
cells expressing CD89, for example, for labeling such cells. For
such use, the binding agent can be linked to a molecule that can be
detected. Thus, the invention provides methods for localizing ex
vivo or in vitro cells expressing CD89. The detectable label can
be, e.g., a radioisotope, a fluorescent compound, an enzyme, or an
enzyme co-factor.
[0231] In one embodiment, the invention provides methods for
detecting the presence of CD89 antigen in a sample, or measuring
the amount of CD89 antigen, comprising contacting the sample, and a
control sample, with a human monoclonal antibody, or an antigen
binding portion thereof, which specifically binds to CD89, under
conditions that allow for formation of a complex between the
antibody or portion thereof and CD89. The formation of a complex is
then detected, wherein a difference complex formation between the
sample compared to the control sample is indicative the presence of
CD89 antigen in the sample.
[0232] In still another embodiment, the invention provides a method
for detecting the presence or quantifying the amount of
Fc-expressing cells in vivo or in vitro. The method comprises (i)
administering to a subject a composition (e.g., a multi- or
bispecific molecule) of the invention or a fragment thereof,
conjugated to a detectable marker; (ii) exposing the subject to a
means for detecting said detectable marker to identify areas
containing Fc-expressing cells.
[0233] The present invention is further illustrated by the
following examples which should not be construed as further
limiting. The contents of all figures and all references, patents
and published patent applications cited throughout this application
are expressly incorporated herein by reference.
EXAMPLES
Example 1
Generation of Transgenic (Cmu Targeted) Mice for the Production of
Fully Human Monoclonal Antibodies to CD89
[0234] Construction of a CMD Targeting Vector
[0235] The plasmid pICEmu contains an EcoRI/XhoI fragment of the
murine Ig heavy chain locus, spanning the mu gene, that was
obtained from a Balb/C genomic lambda phage library (Marcu et al.
Cell 22: 187, 1980). This genomic fragment was subcloned into the
XhoI/EcoRI sites of the plasmid pICEM19H (Marsh et al; Gene 32,
481-485, 1984). The heavy chain sequences included in pICEmu extend
downstream of the EcoRI site located just 3' of the mu intronic
enhancer, to the XhoI site located approximately 1 kb downstream of
the last transmembrane exon of the mu gene; however, much of the mu
switch repeat region has been deleted by passage in E. coli.
[0236] The targeting vector was constructed as follows. A 1.3 kb
HindIII/SmaI fragment was excised from pICEmu and subcloned into
HindIII/SmaI digested pBluescript (Stratagene, La Jolla, Calif.).
This pICEmu fragment extends from the HindIII site located
approximately 1 kb 5' of Cmu1 to the SmaI site located within Cmu1.
The resulting plasmid was digested with SmaI/SpeI and the
approximately 4 kb SmaI/XbaI fragment from pICEmu, extending from
the SmaI site in Cmu1 3' to the XbaI site located just downstream
of the last Cmu exon, was inserted. The resulting plasmid, pTAR1,
was linearized at the SmaI site, and a neo expression cassette
inserted. This cassette consists of the neo gene under the
transcriptional control of the mouse phosphoglycerate kinase (pgk)
promoter (XbaI/TaqI fragment; Adra et al. (1987) Gene 60: 65-74)
and containing the pgk polyadenylation site (PvuII/HindIII
fragment; Boer et al. (1990) Biochemical Genetics 28: 299-308).
This cassette was obtained from the plasmid pKJ1 (described by
Tybulewicz et al. (1991) Cell 65: 1153-1163) from which the neo
cassette was excised as an EcoRI/HindIII fragment and subcloned
into EcoRI/HindIII digested pGEM-7Zf (+) to generate pGEM-7 (KJ1).
The neo cassette was excised from pGEM-7 (KJ1) by EcoRI/SalI
digestion, blunt ended and subcloned into the SmaI site of the
plasmid pTAR1, in the opposite orientation of the genomic Cmu
sequences. The resulting plasmid was linearized with Not I, and a
herpes simplex virus thymidine kinase (tk) cassette was inserted to
allow for enrichment of ES clones bearing homologous recombinants,
as described by Mansour et al. (1988) Nature 336: 348-352. This
cassette consists of the coding sequences of the tk gene bracketed
by the mouse pgk promoter and polyadenylation site, as described by
Tybulewicz et al. (1991) Cell 65: 1153-1163. The resulting CMD
targeting vector contains a total of approximately 5.3 kb of
homology to the heavy chain locus and is designed to generate a
mutant mu gene into which has been inserted a neo expression
cassette in the unique SmaI site of the first Cmu exon. The
targeting vector was linearized with PvuI, which cuts within
plasmid sequences, prior to electroporation into ES cells.
[0237] Generation and Analysis of Targeted ES Cells
[0238] AB-1 ES cells (McMahon, A. P. and Bradley, A., (1990) Cell
62: 1073-1085) were grown on mitotically inactive SNL76/7 cell
feeder layers (ibid.) essentially as described (Robertson, E. J.
(1987) in Teratocarcinomas and Embryonic Stem Cells: a Practical
Approach (E. J. Robertson, ed.) Oxford: IRL Press, p. 71-112). The
linearized CMD targeting vector was electroporated into AB-1 cells
by the methods described Hasty et al. (Hasty, P. R. et al. (1991)
Nature 350: 243-246). Electroporated cells were plated into 100 mm
dishes at a density of 1-2.times.10.sup.6 cells/dish. After 24
hours, G418 (200 micrograms/ml of active component) and FIAU
(5.times.10.sup.-7 M) were added to the medium, and drug-resistant
clones were allowed to develop over 8-9 days. Clones were picked,
trypsinized, divided into two portions, and further expanded. Half
of the cells derived from each clone were then frozen and the other
half analyzed for homologous recombination between vector and
target sequences.
[0239] DNA analysis was carried out by Southern blot hybridization.
DNA was isolated from the clones as described Laird et al. (Laird,
P. W. et al., (1991) Nucleic Acids Res. 19: 4293). Isolated genomic
DNA was digested with SpeI and probed with a 915 bp SacI fragment,
probe A (see FIG. 1), which hybridizes to a sequence between the mu
intronic enhancer and the mu switch region. Probe A detects a 9.9
kb SpeI fragment from the wild type locus, and a diagnostic 7.6 kb
band from a mu locus which has homologously recombined with the CMD
targeting vector (the neo expression cassette contains a SpeI
site). Of 1132 G418 and FIAU resistant clones screened by Southern
blot analysis, 3 displayed the 7.6 kb SpeI band indicative of
homologous recombination at the mu locus. These 3 clones were
further digested with the enzymes BglI, BstXI, and EcoRI to verify
that the vector integrated homologously into the mu gene. When
hybridized with probe A, Southern blots of wild type DNA digested
with BglI, BstXI, or EcoRI produce fragments of 15.7, 7.3, and 12.5
kb, respectively, whereas the presence of a targeted mu allele is
indicated by fragments of 7.7, 6.6, and 14.3 kb, respectively. All
3 positive clones detected by the SpeI digest showed the expected
BglI, BstXI, and EcoRI restriction fragments diagnostic of
insertion of the neo cassette into the Cmu1 exon.
[0240] Generation of Mice Bearing the Mutated mu Gene
[0241] The three targeted ES clones, designated number 264, 272,
and 408, were thawed and injected into C57BL/6J blastocysts as
described by Bradley (Bradley, A. (1987) in Teratocarcinomas and
Embryonic Stem Cells: a Practical Approach. (E. J. Robertson, ed.)
Oxford: IRL Press, p. 113-151). Injected blastocysts were
transferred into the uteri of pseudopregnant females to generate
chimeric mice representing a mixture of cells derived from the
input ES cells and the host blastocyst. The extent of ES cell
contribution to the chimera can be visually estimated by the amount
of agouti coat coloration, derived from the ES cell line, on the
black C57BL/6J background. Clones 272 and 408 produced only low
percentage chimeras (i.e. low percentage of agouti pigmentation)
but clone 264 produced high percentage male chimeras. These
chimeras were bred with C57BL/6J females and agouti offspring were
generated, indicative of germline transmission of the ES cell
genome. Screening for the targeted mu gene was carried out by
Southern blot analysis of BglI digested DNA from tail biopsies (as
described above for analysis of ES cell DNA). Approximately 50% of
the agouti offspring showed a hybridizing BglI band of 7.7 kb in
addition to the wild type band of 15.7 kb, demonstrating a germline
transmission of the targeted mu gene.
[0242] Analysis of Transgenic Mice for Functional Inactivation of
mu Gene
[0243] To determine whether the insertion of the neo cassette into
Cmu1 has inactivated the Ig heavy chain gene, a clone 264 chimera
was bred with a mouse homozygous for the JHD mutation, which
inactivates heavy chain expression as a result of deletion of the
JH gene segments (Chen et al, (1993) Immunol. 5: 647-656). Four
agouti offspring were generated. Serum was obtained from these
animals at the age of 1 month and assayed by ELISA for the presence
of murine IgM. Two of the four offspring were completely lacking
IgM (see Table 1). Genotyping of the four animals by Southern blot
analysis of DNA from tail biopsies by BglI digestion and
hybridization with probe A (see FIG. 1), and by StuI digestion and
hybridization with a 475 bp EcoRI/StuI fragment (ibid.)
demonstrated that the animals which fail to express serum IgM are
those in which one allele of the heavy chain locus carries the JHD
mutation, the other allele the Cmu1 mutation. Mice heterozygous for
the JHD mutation display wild type levels of serum Ig. These data
demonstrate that the Cmu1 mutation inactivates expression of the mu
gene.
1 TABLE 1 Serum IgM Ig H chain Mouse (micrograms/ml) genotype 42
<0.002 CMD/JHD 43 196 +/JHD 44 <0.002 CMD/JHD 45 174 +/JHD
129 .times. BL6 F1 153 +/+ JHD <0.002 JHD/JHD
[0244] Table 1 shows the levels of serum IgM, detected by ELISA,
for mice carrying both the CMD and JHD mutations (CMD/JHD), for
mice heterozygous for the JHD mutation (+/JHD), for wild type
(129Sv.times.C57BL/6J)F1 mice (+/+), and for B cell deficient mice
homozygous for the JHD mutation (JHD/JHD).
Example 2
Generation of HCO12 Transgenic Mice for the Production of Fully
Human Monoclonal Antibodies to CD89
[0245] The HCO12 Human Heavy Chain Transgene
[0246] The HCO12 transgene was generated by coinjection of the 80
kb insert of pHC2 (Taylor et al., 1994, Int. Immunol., 6: 579-591)
and the 25 kb insert of pVx6. The plasmid pVx6 was constructed as
described below.
[0247] An 8.5 kb HindIII/SalI DNA fragment, comprising the germline
human VH1-18 (DP-14) gene together with approximately 2.5 kb of 5'
flanking, and 5 kb of 3' flanking genomic sequence was subcloned
into the plasmid vector pSP72 (Promega, Madison, Wis.) to generate
the plasmid p343.7.16. A 7 kb BamHI/HindIII DNA fragment,
comprising the germline human VH5-51 (DP-73) gene together with
approximately 5 kb of 5' flanking and 1 kb of 3' flanking genomic
sequence, was cloned into the pBR322 based plasmid cloning vector
pGP1f (Taylor et al. 1992, Nucleic Acids Res. 20: 6287-6295), to
generate the plasmid p251f. A new cloning vector derived from pGP1f
pGP1k, was digested with EcoRV/BamHI, and ligated to a 10 kb
EcoRV/BamHI DNA fragment, comprising the germline human VH3-23
(DP47) gene together with approximately 4 kb of 5' flanking and 5
kb of 3' flanking genomic sequence. The resulting plasmid,
p112.2RR.7, was digested with BamHI/SalI and ligated with the 7 kb
purified BamHI/SalI insert of p251f. The resulting plasmid, pVx4,
was digested with XhoI and ligated with the 8.5 kb XhoI/SalI insert
of p343.7.16.
[0248] A clone was obtained with the VH1-18 gene in the same
orientation as the other two V genes. This clone, designated pVx6,
was then digested with NotI and the purified 26 kb insert
coinjected--together with the purified 80 kb NotI insert of pHC2 at
a 1:1 molar ratio--into the pronuclei of one-half day
(C57BL/6J.times.DBA/2J)F2 embryos as described by Hogan et al. (B.
Hogan et al., Manipulating the Mouse Embryo, A Laboratory Manual,
2.sup.nd edition, 1994, Cold Spring Harbor Laboratory Press,
Plainview, N.Y.). Three independent lines of transgenic mice
comprising sequences from both Vx6 and HC2 were established from
mice that developed from the injected embryos. These lines are
designated (HCO12) 14881, (HCO12) 15083, and (HCO12) 15087. Each of
the three lines were then bred with mice comprising the CMD
mutation described in Example 1, the JKD mutation (Chen et al.
1993, EMBO J. 12: 811-820), and the (KCo5)9272 transgene (Fishwild
et al. 1996, Nature Biotechnology 14: 845-851). The resulting mice
express human immunoglobulin heavy and kappa light chain transgenes
in a background homozygous for disruption of the endogenous mouse
heavy and kappa light chain loci.
Example 3
Production of Human Monoclonal Antibodies and Bispecifics Against
CD89
[0249] Human anti-CD89 monoclonal antibodies were generated by
immunizing HCO12 mice with recombinant soluble CD89 antigen.
[0250] In particular, HCO12 mice were initially immunized with 20
.mu.g antigen emulsified in Complete Freund's Adjuvant, followed by
two more immunizations in Incomplete Freund's Adjuvant. Mice were
immunized every 2 weeks by intrapertineal injections.
[0251] Ten days after the final immunization, the human IgG
anti-CD89 titer was determined by ELISA (as described below). Mice
that developed sufficient titer (anti-CD89 IgG response) were IV
boosted with 23 .mu.g antigen at three days and two days prior to
splenectomy. The spleens from responding mice were harvested and
dispersed into single cells.
[0252] To generate hybridomas producing anti-CD89 antibodies,
splenocytes from mice with plasma containing anti-CD89 antibodies
were fused with P3X 63-Ag8.653 cells (deposited with the ATCC under
designation ATCC CRL 1580 nonsecreting mouse myeloma cells) and
PEG. After hybridomas grew out, each well containing hybridomas was
screened for the production of human IgG using an anti-human IgG
ELISA. Positive hybridomas were screened for and selected based on
the following properties: (1) production of human IgG1.kappa.
antibodies, (2) binding to soluble recombinant CD89, and (3)
binding to CD89-expressing immune cells. Three positive clones,
referred to as 7.4 (7F 12), 8.2 (8D2) and 14.1 (14A8) were found to
fit these criteria.
[0253] Solid-phase ELISA based assays were employed in the binding
studies. Briefly, soluble recombinant CD89 in PBS was coated onto
96-well microtiter plates (1 .mu.g/ml) and incubated overnight at
room temperature. The plates were then washed with PBS-0.2%Tween-20
(PBST) and blocked with chicken serum albumin in PBST for 1 hour at
room temperature. Supernatants from the anti-CD89 producing
hybridomas or purified antibody (in PBS) were added to the wells
and incubated for 2 hours at room temperature. The plates were
washed with PBST as above and then incubated with 50 .mu.l of
HRP-conjugated goat-anti-human for 1 hour at room temperature.
After washing, 100 .mu.l of ABTS (150 mg 2,2'-azino-bis
(3-ethylbenzthiazoline-6-sulfonic acid in 500 ml of 0.1 M citric
acid, pH 4.35)/H.sub.2O.sub.2 (10 .mu.l 30% H.sub.2O.sub.2 per 10
ml of ABTS solution) chromagen/substrate solution was added to each
well and the samples read with a microplate reader at a wavelength
of 405 nm.
[0254] Hybridomas which produced human IgG that bound CD89 were
further characterized for isotype using ELISA (Human Kappa) (same
protocol described above). Three cell lines, 7.4, 8.2 and 14.1,
were selected based on the production of antibodies that bind
soluble CD89 having human IgG1.kappa. isotype. Antibodies were
isolated from a Cellmax bioreactor (Cellco, Laguna Hills, Calif.)
using HyQ-CCM1 medium containing 1 to 5% Fetalclone (Hyclone,
Logan, Utah) and purified by column chromatography. Purified
antibodies were extensively dialyzed against 0.3 M sodium carbonate
buffer, pH 9.5, for labeling with fluorescence isothiocyanate
(FITC). A stock FITC solution was prepared by dissolving 1 mg solid
FITC in 1 ml of DMSO. Stock FITC was added dropwise with constant
mixing in an amount to provide 50 .mu.g FITC per mg of antibody
protein. Following the addition of FITC, the solution was incubated
in the dark for 1-3 hours at room temperature. FITC labeled
antibodies were isolated by gel filtration on a Sephadex G-10
column equilibrated in PBS.
[0255] Purified antibodies were further characterized for binding
specificity and activity as described in the following
examples.
Example 4
Characterization of Human Monoclonal Antibodies to CD89
[0256] 1. Binding/Specificity Studies
[0257] Monoclonal antibodies (Mabs) purified from hybridoma
supernatants that showed significant binding to CD89 as detected by
ELISA (e.g., 7.4, 8.2 and 14.1) were further tested as described
below using flow cytometry (FACS analysis) and confirmed to bind to
the following CD89 expressing cells: (1) murine 2a1.6 cells
transformed to express human CD89 ("2a1.6/CD89 cells"), (2) human
PMNL cells ("HuPMN") and (3) PMNL cells isolated from transgenic
mice expressing human CD89 ("Fc.alpha.RITg MsPMN").
[0258] MAb 14.1, in particular, was confirmed to recognize CD89
(Fc.alpha.RI) within extracellular domain 2, outside the
IgA-binding site which distinguishes it from known murine anti-CD89
Mabs, such as My43 (mouse IgM) which blocks the Fc.alpha.RI
ligand-binding domain (Shen, L. et al., 1989 J. Immunol. 143:
4117).
[0259] PMNL Isolation
[0260] Human PMNL were isolated from heparinized venous blood of
healthy volunteers by Ficoll-Histopaque (Sigma) density gradient
centrifugation. PMNL purify determined by cytospin preparations
exceeded 95%, and cell viability was >98% (determined by trypan
blue exclusion).
[0261] Prior to niurine PMNL isolation, mice were injected
subcutaneously with 15 .mu.g polyethylene-glycol granulocyte
colony-stimulating growth factor (PEG-G-CSF, kindly provided by Dr.
J. Andreson, Amgen, Thousand Oaks, Calif.) to increase PMNL
numbers. Blood was collected from the retro-orbital plexus 3 days
later. Erythrocytes were removed by hypotonic lysis, followed by
washing remaining leukocytes three (3) times with RPMI 1640 medium
(Gibco BRL, Grand Island, N.Y.), supplemented with 10% FCS. FACS
analyses, performed on a FACSsan (Becton Dickinson, San Jose,
Calif.), revealed leukocytes to consist of .about.55% PMNL, -40%
lymphocytes, .about.3% monocytes, and .about.1% cosinophils. Cell
viability determined by trypan blue exclusion was always
>95%.
[0262] FACS Analysis 1 (Binding Study)
[0263] 50 microliters antibody dilution was added to 50,000
2a1.6/CD89 cells in 50 microliters Facsbuffer and incubated for
thirty (30) minutes at 4.degree. C. The cells were then washed
three (3) times with 100 microliters Facsbuffer, incubated with
Rabbit (Fab2) anti Hu IgG-FITC for thirty (30) minutes at 4.degree.
C., and washed three (3) times with 100 microliters Facsbuffer. The
cells were resuspended in 200 microliters Facsbuffer. Fluorescence
was determined on a Facscalibur (Becton Dickinson).
[0264] FACS Analysis 2 (Specificity Study 1)
[0265] 25 microliters of 1 mg/ml in Facsbuffer were added to 50,000
2a1.6/CD89 cells in 50 microliters Facsbuffer and incubated for
fifteen (15) minutes at 4.degree. C. 25 microliters antibody
dilution were added and incubated for thirty (30) minutes at
4.degree. C. and washed three (3) times with 100 microliters
Facsbuffer. The cells were then incubated with Rabbit(Fab2) anti Hu
IgG-FITC for thirty (30) minutes at 4.degree. C., washed three (3)
times with 100 microliters Facsbuffer, and resuspended in 200
microliters Facsbuffer. Fluorescence was determined on a
Facscalibur (Becton Dickinson).
[0266] FACS Analysis 3 (Specificity Study 2)
[0267] 50 microliters antibody dilution were added to 50,000
2a1.6/CD89 cells, as well as contol cells: Jurkat/IIIa,
CHO/IIIbNA.2, CHO/IIIbNA. 1, 2a1.6/CD64 or SLC cells in 50
microliters Facsbuffer, incubated for thirty (30) minutes at
4.degree. C., and washed three (3) times with 100 microliters
Facsbuffer. Cells were then incubated with Rabbit (Fab2) anti Hu
IgG-FITC for thirty (30) minutes at 4.degree. C., and washed three
(3) times with 100 microliters Facsbuffer. Cells were resuspended
in 200 microliters Facsbuffer. Fluorescence was determined on a
Facscalibur (Becton Dickinson).
[0268] FACS Analysis 4 (Whole Blood Binding Study)
[0269] 50 microliters antibody dilution were added to 50
microliters Human, Mouse or CD89 Tg mouse whole blood and incubated
for thirty (30) minutes at 4.degree. C. Cells were lysed with FACS
lysis buffer, incubated at 4.degree. C., washed three (3) times
with 100 microliters Facsbuffer, incubated with Rabbit (Fab2) anti
Hu IgG-FITC for thirty (30) minutes at 4.degree. C., and washed
three (3) times with 100 microliters Facsbuffer. Cells were then
resuspended in 200 microliters Facsbuffer. Fluorescence was
determined on a Facscalibur (Becton Dickinson).
[0270] II. Competition Studies
[0271] Mabs 14.1 and 7.4 were tested in blocking studies and
inhibition ELISA as described below for the ability to inhibit
human IgA and Mab My43 (a mouse anti-CD89 antibody) binding to
CD89.
[0272] Like IgA, MY43 binds to CD89 at the natural ligand binding
site and thus competes with IgA binding. Mabs 14.1 and 7.4 were
also tested for the ability to inhibit binding of Mabs A77 and A59
(which binds outside the natural ligand, IgA, binding site) to
CD89.
[0273] Mab 14.1 did not inhibit IgA and MY43 binding, but did
inhibit A77 and A59 binding to CD89, showing that it binds outside
the natural ligand binding site.
[0274] Mab 7.4 did not inhibit IgA, MY43, A77 or A59 binding to
CD89, showing that it also binds outside the natural ligand binding
site, but at a site different from 14.1.
[0275] Blocking Study
[0276] 25 microliters antibody dilution were added to 50,000
2a1.6/cd89 cells in 50 microliters Facsbuffer and incubated for
fifteen (15) minutes at 4.degree. C. 25 microliters of a suboptimal
concentration of A77-FITC, A59-PE or MY43 were added and incubated
for thirty (30) minutes at 4.degree. C. and washed three (3) times
with 100 microliters Facsbuffer. The MY43 treated cells were
incubated with Rabbit (Fab2) anti Hu-IgG-Fc-FITC for thirty (30)
minutes at 4.degree. and washed three (3) times with 100
microliters Facsbuffer. The cells were then resuspended in 200
microliters Facsbuffer. Fluorescence was determined on a
Facscalibur (Becton Dickinson).
[0277] Inhibition ELISA
[0278] A 96 well ELISA (flat) bottom plate was coated with 100
microliters/well soluble recombinant CD89 (1 microgram/ml) in PBS
and incubated overnight at room temperature. The ELISA plate was
emptied and incubated with 100 microliters/well PBS/0.05% Tween 1%
Chicken serum (PBST/Ch) for sixty (60) minutes at room temperature.
The plate was emptied and incubated with an excess of antibody (50
microliters/well) which was diluted in PBST/Ch for ten (10)
minutes. 50 microliters per well of an aIgA2 solution were added in
PBST/Ch in a doses response and incubated for sixty (60) minutes at
room temperature. The plate was then washed three (3) times with
PBS/0.05% Tween (PBST) and incubated with 4E8-biotin 100
microliters per well (Mouse anti IgA) for sixty (60) minutes at
room temperature. The plate was then washed three (3) times with
PBST and incubated with Strep-HRP in PBST/Ch 100 microliters per
well for sixty (60) minutes at room temperature, washed three (3)
times with PBST and developed ELISA with ABTS. Optical density was
read at a wavelength of 405 nm in a Bio-tek reader.
[0279] III. Immuno Precipitation Studies
[0280] Mabs 14.1 and 7.4 were found to immunoprecipitate soluble
recombinant CD89 (sCD89).
[0281] Briefly, a ProtG Sepharose Fast Flow column was washed three
(3) times with PBS. sCD89 was precleared with washed beads in PBS
for two (2) hours at 4.degree. C. The precleared sCD89 was
incubated for two (2) hours at 4.degree. C. with antibodies, mouse
IgG or human IgG. The CD89/IgG solution was washed with Prot G for
one (1) hour at 4.degree. C. and then washed five (5) times with
PBS. The samples were then resuspended in SDS-PAGE sample buffer,
run in a SDS-PAGE gradient gel and then the gel was stained with
Commassie Brilliant Blue.
[0282] IV. Affinity Studies
[0283] The affinity kinetics, i.e., binding equilibrium association
constant (Ka) and dissociation constant (Kd), of MAbs 14.1 and 7.4
were measured as described below.
[0284] The Ka for Mab 14.1 was determined to be about
1.5.times.10.sup.9 and the Kd about 6.8.times.10.sup.-10.
[0285] The Ka for MAb 7.4 was determined to be about
2.0.times.10.sup.8 and the Kd about 5.1.times.10.sup.-9.
[0286] Affinity kinetics were determined using a BIAcore assay by
immobilizing sCD89 to chips and flowing the Mabs over the chips at
various concentrations. Mab capture assays were also performed by
flowing sCD89 over MAbs. Immobilization of the antigen and human
IgG was performed through amine coupling. The kit was purchased
through BIAcore, including chips and buffer. A langmuir model was
used as the fit. Analysis of the data was performed through the
models available on the software associated with the
instrument.
Example 5
Activity of Human Monoclonal Antibodies to CD89
[0287] I. Calcium flux Studies
[0288] Mab 14.1 was tested as follows and shown to induce a calium
flux. Mab 7.4 did not induce a calcium flux.
[0289] 38 microliters SNARF-1 and 38 microliters FLUO-3 were added
to resuspended 3.sup.e6 cells in 1.52 ml medium without serum,
after washing the cells three (3) times. The cells were incubated
in the dark at 37.degree. C. and 5 ml warm (37.degree.) medium
without serum were added and the cells were incubated for another
five (5) minutes at 37.degree. C. The cells were then washed twice
with medium without serum and coated with antibody anti Fc.alpha.R1
and washed again. The cells in Ca++ Mobilisation buffer were
resuspended and run on a flow cytometer for twenty-four (24)
seconds to establish the baseline level. Next, crosslinking
antibody anti HuIgG-Fc cells were added and monitored for four (4)
minutes. Cells used were not incubated with anti Fc.alpha.R1 in
order to establish negative control.
[0290] II. Human C1q Binding Studies
[0291] Mabs 14.1 and 7.4 were tested by ELISA and FACS as described
in the subsections below for the ability to fix hC1q in ELISA and
when bound to CD89 expressing cells (in FACS analysis).
[0292] Mab 14.1 was able to fix hC1q in ELISA and weakly when bound
to cells. Mab 7.4 was able to fix hC1q in ELISA, but not when bound
to cells. The inability of these Mabs to fix hC1q when bound to
cells, which mirrors in vivo conditions, makes them particularly
valuable for use in therapy, e.g., in situations where it is
undesirable to initiate the complement cascade (resulting in target
cell lysis).
[0293] ELISA Analysis
[0294] Briefly, a 96 well ELISA (flat) bottom plate was coated with
100 microliter/well human IgG (3 microgram/ml) in PBS (hIgG1,
hIgG2, hIgG3 and hIGg4 were used as controls), incubated overnight
at room temperature and emptied and then incubated with 100
microliter/well Phosphate/NaCl/Gelatin/Tween buffer (C1q-ELISA
diluent) for sixty (60) minutes at room temperature. The plate was
emptied and incubated with 20 microgram/ml (100 microliter/well),
diluted in C1a-ELISA diluent for sixty (60) minutes at room
temperature, and washed three (3) times with C1q-ELISA diluent.
Next, the plate with Rabbit anti hC1q diluted in C1q-ELISA diluent
100 microliter per well was incubated for sixty (60) minutes at
room temperature, washed three (3) times with C1q-ELISA diluent and
incubated with PO-conjugated Swine anti Rb IgG-Fc diluted in
C1q-ELISA diluent 100 microliter per well for sixty (60) minutes at
room temperature. The plate was then washed three (3) times with
C1q-ELISA diluent. The ELISA was developed with ABTS and the
optical density was read at a wavelength of 405 nm in Bio-tek
reader.
[0295] FACS Analysis
[0296] 25 microliters antibody dilution in C1q-Facsbuffer were
added to 50,000 2a1.6/cd89 cells in 50 microliter Facsbuffer plus
NaCl (C1q-Facsbuffer), incubated for fifteen (15) minutes at
4.degree. C. to which 25 microliter of hC1q (20 microgram/ml) in
C1q-Facsbuffer were added and incubated for thirty (30) minutes at
4.degree. C. The cells were then washed three (3) times with 100
microliter C1q-Facsbuffer, incubated with Rabbit anti hC1q-Fitc for
thirty (30) minutes at 4.degree. C. and washed three (3) times with
100 microliter C1q-Facsbuffer. The cells were resuspended in 200
microliter C1q-Facsbuffer. Fluorescence was determined on a
Facscalibur (Becton Dickinson).
[0297] Equivalents
[0298] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents of the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
Sequence CWU 1
1
8 1 357 DNA Homo sapiens 1 caggtgcaac tggtggagtc tgggggaggc
gtggtccagc ctgggaggtc cctgagactc 60 tcctgtgcag cctctggatt
caccttcagt agttatgttc tgcactgggt ccgccaggct 120 ccaggcaagg
ggctggattg ggtggcagtg atatcagatg atggaaggaa taaatacttc 180
gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat
240 ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgt
gagagaaggg 300 tatagcggca gctggtttga ctactggggc cagggaaccc
tggtcaccgt ctcctca 357 2 119 PRT Homo sapiens 2 Gln Val Gln Leu Val
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Val
Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Asp Trp Val 35 40
45 Ala Val Ile Ser Asp Asp Gly Arg Asn Lys Tyr Phe Ala Asp Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Val Arg Glu Gly Tyr Ser Gly Ser Trp Phe
Asp Tyr Trp Gly Gln Gly 100 105 110 Thr Leu Val Thr Val Ser Ser 115
3 321 DNA Homo sapiens 3 gccatccagt tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60 atcacttgcc gggcaagtca
gggcattagc agtgctttag cctggtatca gcagaaacca 120 gggaaagctc
ctaagctcct gatctatggt gcctccagtt tggaaggtgg ggtcccatca 180
aggttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct
240 gaagattttg caacttatta ctgtcaacag tttaatagtt acccattcac
tttcggccct 300 gggaccaaag tggatatcaa a 321 4 107 PRT Homo sapiens 4
Ala Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5
10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser
Ala 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Ser Leu Glu Gly Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr
Cys Gln Gln Phe Asn Ser Tyr Pro Phe 85 90 95 Thr Phe Gly Pro Gly
Thr Lys Val Asp Ile Lys 100 105 5 357 DNA Homo sapiens 5 caggtgcagc
tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
tcctgtgcag cctctggatt caccttcagt agctatgcta tgcactgggt ccgccaggct
120 ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaagaaa
taaagactac 180 gcagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240 ctgcaaatga acagcctgag agctgaggac
acggctgtgc attactgtgc gaggcttgac 300 tggggatatg atgcttttga
tatctggggc caagggacaa tggtcaccgt ctcttca 357 6 119 PRT Homo sapiens
6 Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1
5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Arg Asn Lys Asp
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val His Tyr Cys 85 90 95 Ala Arg Leu Asp Trp
Gly Tyr Asp Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110 Thr Met Val
Thr Val Ser Ser 115 7 327 DNA Homo sapiens 7 gaaattgtgt tgacgcagtc
tccaggcacc ctgtctttgt ctccagggga aagagccacc 60 ctctcctgca
gggccagtca gagtgttagc agcagctact tagcctggta ccagcagaag 120
cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca
180 gacaggttca gtggcagtgg gtctgggaca gacttcactc tcaccatcag
cagactggag 240 cctgaagatt ttgcagtgta ttactgtcag cagtatggta
gctcacctcc gtacactttt 300 ggccagggga ccaagctgga gatcaaa 327 8 109
PRT Homo sapiens 8 Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser
Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95
Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
* * * * *
References